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The thesis entitled "Analysis of Antiulcer Drugs in Pharmaceutical Formulations" is 
comprised of five chapters. The first chapter describes a general'literature survey of the subject 
matter. The very relevant matters include, a brief discussion on analytical chemistry, "ts role played 
in the field of pharmaceutical and biomedical analysis; various types of analytical techniques which 
are frequently used in the field under discussion; the validation of the developed methxi and the 
statistical treatments adopted during the data analysis to ensure and enforce the validity of the 
method. 
It is well known that the human nature is the most cautious in ^v-^ ry era of the 
development. This lead to the birth of analytical chemistry as it deals with Ihe s'uoy of the iiitrinsic 
properties of the materials to discover their applicability or to warn the conrtrnea on: /uith ihe 
possibility of harm from them. Unlike other areas of studies in scienc;. ihr.rs ..re different 
properties, which heavily influence the results of the analytical methodology at 3ach ar.d every 
step; thus having direct impact on the results. These important properties hav2 been disc issed. 
With the passing time, the demands of the biochemical sciences and the advancement of the 
physical sciences opened the door of sophisticated instrumentation in the field of analytical 
chemistry. The different types of well-established analytical techniques have be'^ n discussed. 
Before or during the development of a method, it is necessary to be very careful of certain 
important things. These concepts have been discussed briefly. Once the analytical method is 
advent, it is necessary to decide its suitability for the intended purpose. This if. known as the 
method validation. Brief discussion of the validation, its components and the different international 
organization involved in it, has been presented. When deciding for the validation of the method, the 
role of statistical analysis can not be ignored. It is the only way to get the most conclusive results 
from the mathematical data obtained during the analysis. It also helps to decide with the progress 
of the work at each step. A detailed discussion of the statistical analysis has been given. A brief 
literature and classification of the concerned pharmaceuticals have also been presented. 
Second chapter describes spectrophotometric methods for the determination of famotidine 
in pure form and in pharmaceutical formulations. This chapter is divided into two sections, namely: 
[A]. Kinetic spectrophotometric determination of famotidine in commercial dosage forms. 
[B]. Application of ninhydrin to spectrophotometric determination of famotidine in drug 
formulations. 
In section A, simple kinetic spectrophotometric method is described for the determination 
of famotidine. The method is based on the oxidation of the drug with alkaline potassium 
permanganate. The reaction is followed spectrophotometrically by measuring the rate of change of 
the absorbance at 610 nm. The initial rate and fixed time methods are adopted for determination 
of drug concentration. The calibration graphs are linear in the ranges of 2 -10 jig mL' and 1 - 8 
^ig mL-' using the initial-rate and fixed-time methods, respectively. The obtained results are 
compared statistically with those given by a reference spectrophotometric method. 
Section B of second chapter describes a simple and fast spectrophotometric procedure for 
the determination of famotidine. The method is based on the interaction of ninhydrin with primary 
amines present in the famotidine. The reaction produces a blue coloured product which absorbed 
maximally at 590 nm. Beer's law obeyed in the concentration range of 5 - 30 jig ml"' with molar 
absorptivity of 6 . 9 9 x 1 L mol"' cm-'. Rigorous statistical analysis of the calibration data was done 
to check and validate the strong correlation of the slope and intercept obtained for the regression 
equation. A plot of joint confidence by the method of Mandel and Linnig was drawn which results in 
an ellipse having its centre at the point of best fit. The obtained experimental data show excellent 
linearity (7= 0.9999). The application of this method on the dosage forms yield accurate and 
precise results. No interference from common excipients were observed. 
The third chapter deals with two simple and sensitive spectrophotometric procedures for 
the assay of roxatidine acetate hydrochloride. Both the methods are based on the charge transfer 
complexation reaction of roxatidine base with 2,3-dichloro 5,6-dicyano 1,4-benzoquirione (DDQ) 
and p<hloranilic acid to give coloured products. Roxatidine base was previously obtained in bulk 
form in chloroform by the treatment of roxatidine acetate hydrochloride with aqueous sodium 
carbonate solution. In each case the absorbance measurements was made at 530 nm. Beer's law 
holds good In the concentration ranges 5 - 65 and 10 - 260 |ig mL' with DDQ and p-chloranilic 
acid, respectively. The slope, intercept and its confidence interval, correlation coefficient, standard 
analytical error, and confidence limit were calculated. The variances were found to be very low 
(2.72x10-5 and 1.53x10-5) for both the methods. The results obtained by applying the proposed 
methods on the locally available formulations were compared with that of the reference methods 
using student's t- and variance ratio F- tests, which indicated excellent agreement in accuracy and 
precision. 
Fourth chapter describes two simple and economical, kinetic spectrophotometric methods 
for the assay of lansoprazole. The methods are based on the formation of chelate complex of the 
drug with Fe(lll) and Zn(ll). The optimum conditions for the reaction are studied and optimised. 
The reaction is followed spectrophotometrically by measuring the rate of change of the absorbance 
of coloured chelates of drug with Fe(lll) and Zn(ll) at 445 and 510 nm, respectively. The 
stoichiometric ratio of lansoprazole to Fe(lll) and Zn(ll) complexes were found to be 1:1 and 2:1, 
respectively. The initial-rate and fixed-time methods are adopted for determination of drug 
concentrations. The calibration graphs are liner in the range of 50 - ZOO [ig ml.-' (initial-rate 
method), 2 0 - 180 ^ig mL-' (fixed-time method) for lansoprazole-Fe(lll) complex and 120 - 300 
(initial-rate method), 90 - 210 ^ig mL^ (fixed-time method) for lansoprazole-Zn(ll) complex. The 
inter-day and intra-day precision data showed good accuracy and precision of the proposed 
procedures for analysis of lansoprazole. The interval hypothesis was also performed which 
indicated that the proposed procedures are not biased. 
The last chapter includes a simple and selective kinetic spectrophotometric method for the 
determination of pantoprazole in pharmaceutical preparations. The procedure is based upon a 
kinetic investigation of the reaction of cited drug with 1-fluoro 2,4-dinitrobenzene in 
dimethylsulphoxide medium at room temperature. The absorbance of the coloured product was 
measured at 420 nm. The initial rates of the reaction were evaluated from the slope of the initial 
tangent to the absorbance-time curves. The plot of logarithm of initial rate of the reaction vs. 
logarithm of molar concentration of the pantoprazole was linear over the range 10 - 20 }ig mL"'. 
The procedure retains its accuracy in the presence of a large excess of its degradate, sulfenic acid, 
which is prepared by degradating the pure drug in borate buffer of pH 8 at room temperature for 
seven days. The results are validated statistically and through recovery studies. The method has 
been successfully applied to the determination of pantoprazole in commercial tablets. Statistical 
comparison of the results with the reference method shows excellent agreement and indicates no 
significant difference in accuracy and precision. 
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The causes of disease are the basic problem associated with the living being from the 
very start of the life on the earth. The way of its removal, i.e. the art of its therapy especially 
dominated by the medicine is an ancient art of human life, though its nature is continuously 
changing in the different era with time. Before century mankind preferred the natural 
products as the medicine. During the period of Paracelsus (16'^ century) to Ehrlich (19"^ 
century) people had undergone major gradual changes in the use of natural products in their 
entire states to either the purified extracts of the material of interest from those or synthetic 
chemically produced materials. This period is regarded as the 'Quintessance to Chemical' [1]. 
With the introduction of chemotherapy system by Louis Pasteur (1822 - 1895), the 
antiprotozoal chemotherapy system followed, resulting in the development of some hypnotic, 
antimalarial and anti-inflammatory drugs, and adrenergic and cholinergic hormones, followed 
by the discovery of antibacterial and antibiotics, analgesics, antihistaminics, vitamins and few 
new hormones. The development and synthesis of drugs had undergone major breakthrough 
after the World War II and a number of antituberculous agents, steroid hormones and 
contraceptives, antipsychotic, anxiolytic and antidepressant psycho-pharmacological drugs 
were discovered. But the increasing number of synthetic drug materials, the extent of its purity, 
the limit of its requirement and the right time for its use and applicability put the question mark 
on the safety of the human life. At such a mean time, the real credit goes to the Food and Drug 
Administration of the United States, which enforced the Pure Food and Drug Act. Thus the 
therapeutic research, drug development and introduction and the pharmaceutical 
manufacturing entered their '"Golden Age" (1940 - 1960). 
With the cautious nature of the human being and growing awareness especially for the 
health hazard reasons, the concept of quality emerged as the prerequisite for safety purposes 
which lead to the interest in the work of analysis. With no name designated and no specificity 
given in the old age, analytical chemistry is the important part of the good quality life in every 
period of the development. Somewhere the quotation of De Quincey can be put as suitable 
evidence in support of this relation. The man of letters penned about his surgeon friend who 
was suffering from a lingering and fatal malady [2]. The surgeon was on the horns of a 
dilemma as he had a family to support and thus eager to continue in work. Because of his 
professional knowledge, he saw the necessity of reducing his daily dose of opium that he took 
to alleviate his pains to a minimum. I now quote the words of De Quincey in this context: "But 
to do this he must first obtain the means of measuring the quantities of opium; not the 
"apparent quantities" as determined by weighing, but the "virtual quantities" after 
allowing for the alloy of varying amounts of impuritiei\ With the skills of the time (about 1820) 
De Quincey's surgeon friend was unable for such an evaluation. He did, however, achieve a 
uniform method of extracting the opium so as to give a fairly constant potency. In the 20'^ 
century, analytical chemistry evolved as one of the important part of the modern science. The 
basic aspect of this interesting science defines it as the "the relationship between the so-called 
intrinsic chemical information of the objects and systems and the information (results, reports) 
provided by the analytical systems (laboratories, on-site analysers etc. J' [3]. 
The chemical analyses is classified into two major classes; qualitative analysis which 
deals with the detection of a constituent in the presence of other components in the analyte 
under investigation while the quantitative analysis determines the proportion of the same. 
With the major emphasis on the qualitative aspect of the analytical chemistry in the 
beginning, the revolution came in the quantitative analytical chemistry, thus broadening the 
width of the whole subject. The credit of such a revolution goes to the finely defined theoretical 
aspects of the analytical chemistry by the scholars of the modern age as well as the advent and 
application of the modern sophisticated analytical instrumentations. Since the primary aim of 
the analytical chemists is to incorporate the quality in the analytical results by minimising the 
difference between the ideal, true information and that produced in the routine work, the above 
mentioned two major factors are playing the key role in deciding it. As far as the theoretical 
aspect is concerned, it can be given the main credit. Any fine-tuning of these aspects causes 
the enhancement of the technical aspects as well as the results obtained by applying the 
appropriate technique. But the overall quality in the analytical result from the adaptation of the 
well-recognised theoretical aspect to the application of a well-established technique depends 
mainly on certain analytical properties. These are capital properties, i.e.; accuracy and 
representativeness; basic, i.e.; sensitivity, selectivity, precision and sampling and accessory 
properties i.e.; expeditiousness, cost-effectiveness and personal related considerations like 
personal safety and comfort. The capital properties are associated with the consistency in the 
results, thus helpful in deciding the quality of the results obtained. But these are basic 
properties, which are mainly responsible for the quality in the output, thus deciding the capital 
properties. The accessory properties, though seems to be less significant, but often have major 
practical implications and some times affect the results heavily. Somewhere, the hierarchy of 
these important components has been presented (in Fig 1.1). 
Goals Quality Properties 
Figure 1.1. Goals of analytical chemistry and their relationships to the analytical quality and 
analytical properties. 
The present generic objectives of the analytical chemists is to obtain the high quality 
analytical information by expending minimum material, consuming less time with least number 
of man-power, involving minimum risk at the lowest cost of expense. The analytical 
methodology adapted chiefly depends on the basic and accessory properties. The basic 
components of these properties are strongly related and heavily affect each other. Any 
excellency or simple enhancement in any of them can be achieved at the cost of another one. 
Fig. 1.2a shows their interdependence in a balanced ideal position while Figs. 1.2b and c 
indicate the results due to the alterations made to achieve an improvement on the different 
sides. 
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Figure 1.2. Analytical tetrahedra showing interdependence of the analytical properties. 
Pharmaceutical analysis is a well-established section in the field of analytical chemistry 
with impressive advancements during the last few decades. Unlike other consumable items in 
the daily life, the presence of impurities and the alterations in the recommended therapeutic 
amount of the drug may show adverse toxicological effects which can be life threatening. The 
top goal of this section is to secure the safety of the drug products by qualitatively identifying 
the impurities associated with it and also by quantifying the active drug substances as per the 
requirement. 
The requirement of quality, quantity, purity and safety of pharmaceutical formulations 
warrants a careful thought by every one associated with this area. Due to easy availability of 
sub-standard drugs and medicines in the markets of the developing countries, it is crucial to 
assay drugs in dosage forms. Hence development of rapid, simple and cost-effective analytical 
methods for the analysis of drugs are the need of the day in public defence. 
In the field of drug analysis volumetric methods either direct or indirect, have their own 
importance due to their inherent simplicity. Owing to this, a large number of official methods for 
the determination of pharmaceuticals in the pharmacopoeias are based on titrimetry [ 4 - 6 ] . 
Though it is the oldest technique in the market now but still having their recognition in the field 
of scientific research. 
Chromatographic methods have many applications in trace analysis and sometimes 
prove it as the only way. The different types of chromatographic methods such as paper 
chromatography, thin layer chromatography, column chromatography, capillary 
electrochromatography, high performance thin layer chromatography, high performance liquid 
chromatography and gas chromatography, have most frequent applications in the field of 
pharmaceutical and biomedical analyses. Thin layer chromatography (TLC) is a simple, in-
expensive and rapid technique, having wide applications for the separation and identification of 
impurities and degraded products [7]. Capillary electrochromatography (CEC) is a method in 
which liquid mobile phase is driven through a stationary phase in a packed capillary column by 
the electro-osmotic flow generated by a large difference in potential across the column [8 -
11]. CEC previously has been utilised for the separation of certain pharmaceuticals; an 
interesting example is that of a diastereoisomeric mixture not successfully separated on a chiral 
HPLC column, which clearly shows its considerable advantage [12]. Among all the 
chromatographic methods, high performance liquid chromatography is most acceptable 
nowadays due to its sensitivity and selectivity even in a multicomponent mixture. It is widely 
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used for the identification of drugs in plasma and dosage forms [13-26], and creating its own 
position in the dissolution monographs of pharmacopoeias for the assay of drugs in dissolution 
fluids [27, 28]. 
Electrochemical methods are characterised by high sensitivity, selectivity and accuracy. 
These methods are based on the basic electrical parameters like current (I), resistance (R) and 
voltage (V), which have been utilised alone or in combination for analytical purposes. 
Pharmaceuticals containing phenolic, amino, heterocyclic nitrogen, ketonic or aldehyde group 
undergo oxidation at their characteristic potentials and hence selectivity of the technique is 
increased. Important electrochemical techniques such as amperometry, conductometry, 
potentiometry, anodic and cathodic stripping voltammetry, differential pulse voltammetry and 
polarography have been used in drug analysis [29]. Ion-selective electrodes are 
electrochemical sensors that allow potentiometric measurements of the activity of particular 
species in aqueous and mixed solvents, or partial pressures of dissolved gases in water [30]. 
Potentiometric titrations are also reported in the pharmacopoeias as the standard method for 
the determination of certain drug substances [31-33]. Bersier has reviewed the importance of 
these techniques in pharmaceutical analysis [34]. 
Spectroscopic methods are widely used for the assay of drugs in pharmaceutical 
formulations. The most commonly used techniques for quantitative analysis are ultraviolet (UV) 
and visible spectrophotometry. It has become an established and fundamental technique in 
pharmaceutical research and analysis as well as in the broad area of organic and inorganic 
analysis. Conventional UV-spectrophotometric methods are simple, fast and economical and do 
not need any elaborate preparatory step for the sample prior to assay. Endriz [35] has 
described an UV-spectrophotometric method for the determination of heroin hydrochloride, 
methapyrilene hydrochloride, and quinine hydrochloride in mixtures. The spectra for heroin, 
methapyrilene, and quinine show points of maximum absorption at 280 nm, 313 nm and 348 
nm, respectively. Methapyrilene and quinine do not seriously interfere with the heroin 
maximum, and methapyrilene in dilute acid solution absorbs only slightly at the quinine 
maximum of 348 nm. The procedure is fast and accurate enough for forensic purposes. 
Analyses of chloramphenicol and tetracycline hydrochloride [36] and phenobarbital and 
pentobarbital in pharmaceutical formulation [37] are further examples of the utility of UV-
spectrophotometry in this area. Because of the sensitivity of the UV method, the amount of 
sample required for the spectral identification is very small; drug levels and metabolites have 
been determined in biological tissues and fluids after separation and extraction. Since most 
materials are not photosensitive, the technique is non-destructive, and the metabolite or drug 
can be recovered for further testing. However, these methods are inadequate in the presence 
of other components (like any drug of combination, excipients or decomposition products) 
showing similar UV spectra [38]. 
Photocolorimetric methods of analysis are performed in the visible region of light. They 
are based on the measurement of the absorbance of the coloured compounds. Usually, the 
analyte being colourless, they are reacted with the suitable chemical reagents in order to 
convert them in coloured compounds. Simple colorimetric and UV methods continue to be 
popular for carrying. out single-component assays on a variety of formulated products. 
Representative examples of some of the many assays that have been published are given in 
Table 1.1. [39-76] 
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In the course of this discussion, the importance of computer-aided spectrophotometric 
determination of multicomponent systems can not be ignored. The quantitative 
spectrophotometric analysis of active ingredients in a solution containing more than two 
substances can be difficult to achieve by means of the traditional methods. In order to resolve 
this problem, several papers were published on the application of least squares method and 
orthogonal polynomials for the analysis of multicomponent systems [77-82]. 
Impurities present on the particle surfaces, e.g. from residual mother liquor, may be 
low in terms of percentage but they may change in a significant way the behaviour of the 
powder in the manufacturing process or in the final medicinal product. Therefore, a 
methodology is needed to detect such deficiencies at the surfaces or in the upper layers of the 
powder. Spectroscopic reflectance technique of sufficient sensitivity and precision could be of 
help to discriminate between apparently identical materials from different sources or to detect 
inconsistencies between the batches from the same source. 
Difference spectrophotometry is an important and useful technique used in the 
determination of medicinal substances by eliminating specific interference from the degradation 
products, co-formulated drugs and non-specific irrelevant absorption from the formulation 
matrix. The technique involves reproducible alterations of the spectral properties of the 
absorbance difference between two solutions, provided that the absorbance of the other 
absorbing substance is not affected by the reagent(s) used to alter the spectral property [83 . 
Derivative spectrophotometry is an analytical technique of great utility for both 
qualitative and quantitative information from spectra composed of unresolved bands. Although 
it was introduced more than thirty years ago [84-85] and has advantages for the solution of 
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specific analytical problems. The derivative method has found applications not only in the UV-
visible spectrophotometry, but also in infrared [87], atomic absorption [88], flame emission 
spectrometry [89] and fluorimetry [90, 91]. The use of derivative spectrometry is not 
restricted to special cases, but may be of advantage whenever quantitative study of normal 
spectra is difficult. Its disadvantage is that the differentiation degrades the signal-to-noise ratio, 
so that some form of smoothing is required in conjunction with the differentiation [92]. 
Even though many pharmaceuticals show native fluorescence, there is also an 
important group of compounds, which is not fluorescent, can be determined by using 
fluorescent probes through derivatisation reactions. An account of the fluorescent probes more 
widely used for the determination of drugs and related compounds has been reviewed [93]. 
Near infrared (NIR) spectroscopy is a technique which has found its way into 
pharmaceutical control laboratories in recent years for raw material identification, water 
analysis and other pharmaceutical analyses [94-99]. Nuclear magnetic resonance (NMR) 
spectroscopy is a well-known spectroscopic technique specially used for the qualitative 
characterisation of the chemicals. In the recent attempts, NMR is also used as the sensitive 
quantitative method; a mini review has been presented in this context [100]. Moreover, NMR 
spectroscopy is favoured by chemists as a powerful technique for molecular structure 
determination. 
Chemiluminescence is a powerful tool for drug analysis since its detection limits are 
extremely low, its instrumentation is very simple and of low cost. In combination with the 
derivatisation techniques in order to increase sensitivity, it has a wide range of applications. 
The excellent sensitivity and the versatility of the chemiluminometric methods of analysis are 
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the main reason for the recent surge of interest in chemiluminescence. Certain drugs have 
been analysed based on the phenomena of chemiluminescence in liquid phase [101-103]. 
Flow injection analysis (FIA) is characterised by its simplicity, speed and the use of in-
expensive equipment. In FIA, as a general principle [104-107], a quantity of accurately 
measured dissolved sample is injected or introduced into the carrier stream flowing through the 
system tubing, with or without additional changes like chemical reaction etc., occurring between 
the sample and the carrier. As the analyte (or its reaction product) passes through the 
continuous detector, a transient signal is generated and recorded. Therefore, FIA has certain 
clear advantages like (i) reduced reagent consumption [108]; (i i) high sampling frequency 
[109]; (i i i) safety in applying toxic reagents because the whole analysis proceeds in a closed 
system; and (iv) increased selectivity when the analyte is accompanied by more slowly reacting 
components. This technique has been utilised successfully in the determination of some 
compounds of pharmaceutical interest [29,110,111], In the recent years, atomic absorption 
and emission spectrophotometry is also frequently used in the field of pharmaceutical analysis 
[112-114]. 
In the recent period, analysts are much interested in coupling the chromatographic 
techniques with that of the spectroscopic techniques. The advent of liquid chromatography with 
mass spectrometry [115], gas chromatography with tandem mass spectrometry and liquid 
chromatography-electrospray tandem mass spectrometry are good examples. Hirsch et. al 
have determined the antibiotics using chromatography-electrospray tandem mass 
spectrometry. Dielectric relaxation spectroscopy and x-ray powder diffractometry are also 
utilised for the identification of pharmaceuticals [116,117]. The safety of a drug product is 
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dependent not only on the toxicological properties of the active drug substance itself, but also 
on the impurities that it contains. Monitoring of drug substance's impurities is routinely 
accomplished using HPLC. However, HPLC retention times can vary, resulting in uncertainty as 
to whether a peak at a new retention time is a new impurity. Because standards of the minor 
impurities (less than 0.1% by area) are not usually available, some method is needed to 
characterise each of these peaks without isolating them. This on-line characterisation might be 
accomplished using UV diode array spectral matching [118]. 
Whenever the question of mathematical and statistical treatments arises, the role of 
chemometrics can not be ignored. Chemometrics is defined as "the chemical discipline that 
uses mathematical, statistical and other methods of formal logic to design or select optimal 
procedures and experiments, and provide maximum chemical information by analysing chemical 
data" [119,120], Chemometrics is the science that helps to make good use of information 
technology in the chemical analysis and to develop intelligent analysers, i.e. that automatically 
select the correct method for a given problem, carry it out, validate it and interpret the results. 
Kinetic method of analysis, which is in fact, the study of the measurement of 
concentration changes (detected via signal changes in a reactant, which may be the analyte 
itself) with time after the sample and reagents have been mixed, is developing since late 
1950s. They are not only the good choices for the drug analysis but very relevant to analytical 
chemistry in at least four respects: (a) it allows the elucidation of the physical, chemical and 
physico-chemical mechanisms on which analytical processes are based and hence their rational 
optimisation; (b) it facilitates the development of new analytical methods and techniques that 
are otherwise unattainable if the dynamic aspects are not dealt with; (c) it is the foundation of 
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reaction rate methods (kinetic determinations); and (d) it contributes as sensitivity, selectivity 
and precision. The principles and applications of the kinetic methods have been reviewed [121-
123]. Kinetic methods are generally rapid, reproducible and involve simple instrumentation. 
Though there are different modes of calibration in kinetic method, but the reaction rate 
methods involve two general aspects, which endow them with higher selectivity than equilibrium 
methods, namely the scarcity of parasitic blank signals and the possibility of using kinetic 
discrimination. In case of very fast reactions, the automatic handling is preferred for better and 
more accurate results; so the automation of the instrumentation is required. They can also be 
used to enhance the reproducibility and rapidity of slow reactions. Since kinetic methods of 
analysis require accurate timing, careful control over experimental conditions, precise sample 
and reagent preparation, proportioning and mixing, and accurate measurements of dynamic 
signals, hence they are well suited to intelligent automation. Kinetic automatic techniques are 
generally based on open systems, among the most popular of which are stopped flow (SF) 
system [124] and the continuous addition of reagent (CAR) technique. Several drugs have 
been determined by using the CAR technique [125-128] with photometric [129,130] and 
fluorimetric detection [131]. On the other hand, the CAR technique has been extended to 
chemiluminescence (CL) reactions as CAR chemiluminescence spectrometry (CARCL), a new 
approach, which have proved outstanding for the analysis of drugs and other substances of 
analytical interest. The use of catalysts to accelerate analytical reactions is feasible with both 
reaction rate and equilibrium determinations. In this concern, the use of micellar media in 
kinetic methods is recently encouraged to enhance the rate of reaction (through miceflar 
catalysis) which in turn reduces the time of analysis and also improves the sensitivity and 
selectivity [132-135]. Multicomponent kinetic determinations, often called as differential rate 
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methods, are also receiving a good deal of current attention in research laboratories. The 
various approaches to multicomponent determinations have been reviewed recently by Perez-
Bendito [136]. One new approach that has been proposed for dealing with overlapping 
spectra is the kinetic wavelength-pair method [137]. For a mixture of two components, the 
method relies on measuring the difference in the rate of change of absorbance with time at two 
pre-set wavelength pairs {four wavelengths). Another method called as the H-point standard 
addition method [138] proposed by Bosch-Reig et ai is capable of kinetic determination of 
components with overlapping spectra in their binary mixture. 
From the manufacturing to the packaging stage, various sources are causing 
impurification of the product. Such impurities may be organic or inorganic type, or the residual 
solvents used to create the desired crystal morphology, the trace of starting materials 
remaining unreacted, the remaining intermediate or bye-products, reagents and catalysts etc. 
Usually pharmaceuticals are very sensitive to the style of storage and class of packaging that 
ultimately causes degradation of the actual products. Unlike other consumable products in the 
daily life, any abnormality in the recommended dosage amount of a pharmaceutical compound 
or the presence of impurity may show adverse toxicological effects. 
Once the pharmaceutical product is produced in bulk or prepared and supplied in the 
commercial form, very crucial questions arise that whether the manufactured product is pure or 
impure; is the supplied form is as per the requirement; and so many similar other questions 
threatening the one associated with it. The ignorance of such crucial questions may be life 
threatening to one expected to be associated with it. The efforts of analytical chemists and the 
role of analytical techniques are the only way to answer these questions. They are responsible 
to satisfy everyone from the manufacturing industries to the market. 
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As mentioned above, the safety of drug products are dependent not only on the 
toxicological properties of the active drug substances itself but also on the impurities that it 
contains. The requirements of quality, quantity, purity and safety of pharmaceutical 
formulations warrant a careful thought by every one associated with this area. Due to easy 
availability of sub-standard drugs and medicines in the markets of the developing countries, it 
is crucial to assay drugs in dosage forms. Hence development of rapid, simple and cost-
effective analytical methods for the analysis of drugs are the need of the day in public defence. 
The increasing emphasis on the pharmacokinetic, bioavailability and therapeutic 
monitoring of drugs has placed a heavy burden on drug analysts. Reliable measurements of 
very low levels of drugs in complex matrices are frequently required. Because of the vast 
number of drugs introduced every year, more and more methods for drugs and metabolite 
determination are being developed either for routine or research use. Analytical procedures are 
used throughout the drug development and the manufacturing of drug substances and drug 
products. Important decisions such as the establishment of the shelf-life from stability studies, 
the need for additional toxicological trials if new impurities appear or if known impurities exceed 
the qualified levels, the reworking of batches or batch release or rejection are based on 
analytical results. In order to make the right decisions and to avoid additional work, an 
appropriate performance of the analytical procedure is essential and this needs the "suitability 
of the method for its intended use ". 
The overall responsibility of an analytical chemist does not reach to its end here. Once 
a method is developed for the determination of a pharmaceutical product, another question, 
not less crucial than the previous one arises, i.e., is the developed method reliable; may it 
guarantee the quality produced as per the requirement. If yes, how? 
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For a number of years analytical chemists in the field of pharmaceutical and biomedical 
analysis have learned how to demonstrate that their methods have a performance that can 
guarantee reliable results. After the advent of good laboratory practice (GLP), we know this 
exercise as validation of analytical methods. 
Once an analytical method is advent, it is important to validate the method before it 
should be recommended for the routine analysis. Method validation of analytical procedure, i.e. 
the proof of its suitability for the intended purpose, is an important component in determining 
the reliability and reproducibility of the methods and is required for any regulatory submission. 
The method should be defensible with respect to regulatory requirements and reliable by 
incorporating statistical analysis to evaluate its performance. Validation of analytical methods 
has been the subject of discussion in recent years [139-142]. The procedure of validation 
requires the calculation and fitting of the experimental data within a standard fixed criteria. 
Statistical techniques are used to evaluate the linearity, precision, accuracy, 
robustness/ruggedness, sensitivity (limit of detection and quantitation) and specificity etc. 
Other aspects needing to be considered include identification and handling of samples prior to 
analysis, stability of samples under various storage conditions and the continuous assessment 
(quality control) of the method during its routine use. Before an analytical method is used for 
routine analysis it must be demonstrated first that the method fulfils certain performance 
criteria, when this has been documented, the method is said to be validated. 
There are several international organisations and regulatory authorities which are 
involved in fixing the criteria for the validation. Some of them are listed below (Table 1.2). In 
the field of drug analysis, it is very clear that the definitions cover the entire field of analytical 
chemistry from bioanalysis to substance and product analysis. 
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Table 1.2. Validation of analytical methods - international definitions. 
Organisation Applicability Remarks 
IUPAC Worldwide 
ILAC Worldwide 
WELAC Europe 
ICH Europe,Japan, USA Only pharmaceutical products. 
ISO Worldwide Lacks definitions of selectivity and 
specificity. 
Abbreviations: iUPAC, International Union of Pure and Applied Chemistry; I LAC, International Laboratory 
Accreditation Conference; WELAC, Western European Laboratory Accreditation Co-operation; ICH, International 
Conference On Harmonisation; ISO, Intemational Organisation for Standardisation. 
Those specifications which are generally accepted for validation include (i) method 
selectivity/ specificity, (11) sensitivity (limit of detection and quantitation), (iii) linearity 
(relationship between the response and concentration), (iv) accuracy, (v) precision, (vi) 
recovery and (vil) robustness/ruggedness. 
Before proceeding for the advent of a validated analytical procedure, an authenticated 
analytical reference must be available to prepare the standard reference solution. The actual 
nature of the compound, i.e. whether it is a free base or salt should be known. The stability of 
the compound should be continuously monitored to exactly know the duration of its use. It must 
be continuously checked for any contamination or impurity. The optimum conditions of the 
method to be proposed must be optimised with respect to the various aspects/variables like 
the suitable amount of the standard reference to be used for the optimisation process, actual 
sufficient amount of different reagents, the enough time for the completion of the analytical 
reaction, the suitable extractant, extraction scheme and the actual volume of the extractant to 
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be used in order to remove the interferents, the right way to store the analyte under 
consideration and an appropriate sampling for enhanced representativeness. These can be 
regarded as the prerequisites of the validation. 
The International Conference on the Harmonisation of the Technical Requirements for 
Registration of Pharmaceuticals for Human Use has harmonised the requirements in two 
guidelines [143,144]. The first one summarises and defines the validation characteristics 
needed for various types of test procedures; the second one extends the previous text to 
include the experimental data required and some statistical interpretation. These guidelines 
serve as a basis world-wide, both for regulatory authorities and industry and bring the 
importance of a proper validation to the attention of all those involved in the process of 
submission. In order to fulfil the validation responsibilities properly, the background of the 
validation parameters and their consequences must be understood. Normally evaluated 
validation characteristics and their minimum number of determinations (if applicable) are listed 
in Table 1.3 [144]. 
There has been controversy regarding the technical term for the validation characteristic, i.e. 
specificity vs. selectivity, and the current definition of ICH is not clear in this respect. A clear 
distinction must be made between the terms "specific""selective". A specific reaction 
or test is one that occurs only with the substance of interest, while a selective reaction or test 
is one that can occur with other substances but exhibits a degree of preference for the 
substance of interest. Few reactions are specific, but many exhibit selectivity. WELAC refers the 
selectivity of a method to the extent to which it can determine particular analyte(s) in a complex 
mixture without interference from other components in the mixture. A method, which is perfectly 
selective for an analyte or a group of analytes, is said to be specific. Thus a specific test 
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Table 1.3. Validation characteristics normally evaluated for the different types of procedures [143] 
and the minimum number of determinations required (if applicable) [144]. 
Validation Minimum number Test procedure 
Parameters 
identity Impurities 
Quantitative Limit 
Assay 
Specificity'' Yes Yes Yes Yes 
Linearity 5 concentrations No Yes No Yes 
Range No Yes No Yes 
Accuracy 9 determinations over 3 
concentrations (e.g. 3x3) 
No Yes No Yes 
Precision 
Repeatability 6 determinations at 100% or 9 
determinations over 3 concentration 
levels (e.g. 3x3). 
No Yes No Yes 
Intermediate 2 series No Yes No Yes 
Precision 
Reproducibility 
Detection 
limit 
No Nod Yes No 
Quantitation 
limit 
No Yes No No 
I^ncluding dissolution, content potency. 
^ Lack of specificity of one analytical procedure could be compensated by other supporting analytical 
procedure(s). 
Intermediate precision sufficient for submission. 
^May be needed in some cases. 
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procedure measures quantitatively a chemical or a physical parameter of functional group of 
one or more different analytes in the sample matrix while a selective one detect qualitatively the 
analyte in the presence of components which may be expected to be present in the sample 
matrix. Fig. 1.3 gives a graphical presentation for the differentiation between selectivity and 
specificity. Specificity is the critical basis for each analytical procedure. Therefore, the 
experimental studies should be carefully planned and justified. The achievable specificity is 
limited by the intrinsic performance of the analytical procedure. The necessary specificity is 
dependent on the requirements of the control test. Adequate (overall) specificity may be 
achieved by using selective methods such as Liquid chromatography or by confirming the 
results of non-specific methods (titration or UV spectroscopy which are expected to include 
closely related substances) with selective purity tests. 
100% 
g o 
.t (0 
15 B 
c ^ .2> CO 
(0 
(a) 
Non-Specific 
w 100%, 
® _ 0) 
2. E C O O 
o" >t: (0 « ® 
c .o" CO 
w £ CO 
Not to be "Scaled" or graded 
(b) 
Degree of selectivity (%) 100 
Fig. 1.3. Graphical demonstration of selectivity and specificity. The percentage of the 
measured signal attributable to the analyte alone (on the K-axis) is given as a 
function of the degree of selectivity (b). A perfectly selective method is said to be 
specific (a). 
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Depending on the test method, appropriate discrimination and/or lack of interference 
of substances likely to be present should be demonstrated, for example choosing a specific 
wavelength or detection mode (U.V., Fluorescence, I.R., electrochemistry, etc.). This includes 
checking of known substances (available expected components, such as starting materials, 
intermediates, excipients, contaminants etc.) as well as samples from forced degradation and 
accelerated stability storage. When stress conditions are applied (heat, light, acid, base, 
peroxide), care should be taken to not overdegrade the sample, thus producing secondary and 
"artificial" degradation products with no relevance to "real" storage conditions. A general rule of 
thumb is to degrade the samples to no more than 90% of their original value. 
For chromatographic methods, specificity may be demonstrated by adequate resolution 
(for the intended purpose), verification of the mass balance, by peak purity checks (Diode 
array detection, MS etc.), or verification by independent methods (scientific studies with 
additional non routine tests, changes in separation mechanisms or conditions, hyphenated 
techniques (LC/MS, GC/NIS), preparative fractionation, IR, NMR). 
Detection limit (DL) is the lowest amount of analyte that can be detected, as it (the 
analyte) yields instrumental response greater than a blank, but can not be quantified. It is a 
parameter of "limit tes^"and expected to produce a response, which is significantly different 
from that of a blank. On the other hand, quantitation limit (QL) is a parameter of 
"determination test" and can be defined as the lowest concentration of analyte that can be 
measured and quantified with acceptable precision and accuracy. Hence, it is the lowest 
concentration included in the standard curve and is used to interpolate unknown sample 
concentration. One should be aware that the determined QL (or DL) is strongly related to the 
equipment actually used as well as to the time of determination. They may represent more 
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system parameters than characteristics of the analytical procedure. In cases where a general 
QL is required, as in pharmaceutical analysis, it is essential to define a realistic QL {or DL) for 
the analytical procedure, independently from the equipment used, because this limit has 
important consequences (e.g. for the reporting threshold for impurities or for method transfer). 
It may be derived by taking QL (or DL) from various instruments into account 
("intermediate QL", during the development process) or can be defined taking the 
requirements of the objective (specification limits imposed by toxicology or by a qualified 
impurity profile) into consideration. For example, a QL that amounts to 50% (or at least 3 
standard deviations) of the specification limit would allow an appropriate quantitation. For 
unknown impurities, the ICH reporting thresholds of 0.05% or 0.03% can be defined as QL. 
During validation, it is just verified, that the actual QL is below the defined limit (regardless how 
much below). The validity of the determined DL/QL should be routinely confirmed within the 
system suitability test (visually or from the signal-to-noise ratio). There are different 
approaches to calculate the DL and QL. One of them is the calculation from noise. This is a very 
straightforward procedure, but very dependent on the operator. Care should also be taken to 
avoid the interpretation of baseline trends as "noise". Only noise signals with a "peak width" 
similar to the analyte to be determined can influence its detection and determination. It should 
also be taken into account that the results represent signal (peak) heights. This approach can 
be used for chromatographic methods. The (random) fluctuations of the baseline while 
performing a blank injection is regarded as "noise". It is recommended to obtain the difference 
between the highest and the lowest signal (amplitude) in a range corresponding to at least 20 
peak widths of the (expected) analyte peak. DL and QL are defined as the 3.3 and 10 fold, 
respectively, of the noise (signal-to-noise ratio) [144-146]. 
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DL and QL can be calculated from the standard deviation of the blanks. This approach 
is usually performed with instrumental methods. Measuring a blank sample, the standard 
deviation is calculated from the numerical outputs. DL and QL are defined as the 3.3 and 10 
fold, respectively, of the standard deviation of the blank. The values are converted to a 
concentration by the slope of a corresponding calibration line [144]. 
^ b 
If calibrations are used to quantify the analyte, the intercept can be regarded as an 
extrapolation of a blank determination. DL and QL are defined as the 3.3 and 10 fold, 
respectively, of the standard deviation of the intercept. The values are converted to a 
concentration by the slope of a corresponding calibration line. 
b b 
Where Sa is the standard deviation of the intercept and b is the slope. 
The residual standard deviation of the regression line is regarded as a measure of the 
variability of the experimental determination. DL and QL are defined as the 3.3 and 10 fold, 
respectively, of the residual standard deviation. The values are converted to a concentration by 
the slope of a corresponding calibration line [144]. The residual standard deviation is strongly 
influenced by the absolute magnitude of the signal values (weighting effect, homogeneity of 
variances and therefore by the concentration range used for the linear regression. This range 
should not exceed the ten fold of the DL. In this range, the variances can be expected to be 
s s homogeneous [147]. DL =3,3*— g / , = 10 * — 
b h 
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The prediction interval of the regression line is regarded as a measure of the variability 
of the experimental determination. This interval can be interpreted as the probability 
distribution of determinations, which can be experimentally expected. The analyte 
concentration, whose probability distribution has a 50% overlapping with the distribution of the 
blank, is defined as the detection limit. With respect to the quantitation limit the overlapping is 
reduced to 5%. Hence, a reliable quantitation is possible in the latter case (Figs. 1.4a and b). 
Fig.1.4 Probability distribution for the blank (BL) and the analyte (AN). Error probability 
(shaded area): a) 50% b) 5%. 
The prediction interval is strongly influenced by the absolute magnitude of the signal 
values (weighting effect, homogeneity of variances) and therefore by the concentration range 
used for the linear regression. This range should not exceed the ten fold of the DL. In this 
range, the variances can be expected to be homogeneous. The homogeneity of variances over 
the whole range (homoscedasticity) is a prerequisite for an unweighted linear regression 
because the absolute deviation of the values from the regression line is used for the 
calculation. 
This can be verified by performing a suitable number of repeated measurements (for 
say n = 6 -10) at the minimum and the maximum of the required linear range, respectively. As 
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statistical procedures, the F-Test or the Cochran-test can be applied. However, in 
pharmaceutical analyses, as the concentration range of interest is usually not very large, it is 
not required to perform a separate test for the homogeneity of variances. In general, the 
homogeneity of variances is maintained over about two orders of magnitude when using UV 
absorbance (within the linear range of the detector/instrument). 
The uncertainty of a given concentration corresponds to half the horizontal prediction 
interval around the regression line at this concentration. A repeated analysis is expected (at 
the defined level of statistical significance) to give a value anywhere in this range. The relative 
value is the ratio between the uncertainty and the corresponding concentration. As this value 
represents a measure of the reliability of a determination at the corresponding concentration 
(Fig. 1.5), DL and QL can be directly calculated by definition of an acceptable relative 
uncertainty. What is the relationship between the relative uncertainty of a given concentration 
and the relative standard deviation of its signal(s)? The latter describes the variability in the 
past, corresponding to an interval around the mean which includes 68% of the normally 
distributed signal values (vertically). The relative uncertainty is based on the prediction interval, 
which indicates the variability of experimental values expected in the future (at the given level 
of statistical confidence, e.g. 95%). Additionally, the uncertainties are calculated with respect to 
concentrations (horizontal prediction intervals). 
Fig. 1.5 Relative uncertainty as a function of concentration 
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Therefore, the sensitivity (slope) of the calibration line has also an influence. Roughly, the 
relative uncertainty can be estimated as 3 to 5 fold of the signal precision at the given 
concentration. It should be noted that the uncertainty function displays a minimum, i.e. not 
each uncertainty value has a corresponding concentration. For small relative uncertainties, 
there is no solution for the equation, as in the shown example for values below 15%. 
Calibration range is defined by the expected concentration in the samples, and will be 
usually in the linear range of the detector for that analyte, where the determined response is 
directly proportional to the concentration The calibration range should neither be too wide nor 
too narrow [140]. Least square linear regression is normally used to define the calibration line 
mathematically. The range of an assay method can also be defined as the concentration 
intervals over which an analyte can be measured with acceptable precision and accuracy. 
Not all the characteristics included in the validation criteria as mentioned above are 
necessarily required to be demonstrated in every case but the evaluation of the linearity of the 
relationship between the actual analyte concentration and the test result from the method, 
however, is required for quantitation testing for impurities and for assay methods [94]. The 
requirement for linearity is independent of the technology used to ascertain the analyte 
concentration. This term holds good for analytical methodology from manual wet chemistry to 
the latest high-tech instruments. Linearity is defined as "the ability of analytical procedure 
(within a given range) to obtain test results which are directly proportional to the concentration 
(amount) of analyte in the sample" [143]. In some cases, to obtain linearity between assays 
and sample concentration, the test data may have to be subjected to a mathematical 
transformation prior to the regression analysis. It means in case of a non-linear relation 
suitable mathematical function may be used for the linearisation process. If there is a linear 
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relationship, test results should be evaluated by appropriate statistical methods, for example, 
by the calculation of regression line by the method of least square [144]. The requirements 
and relevant parameters for the various calibrations are given in Table 1.4. 
Table 1.4. Requirements for the different calibration modes with relevant parameters. 
Quantitation Requirements Relevant parameters 
Single Point 
Calibration 
External standard 
Linear Function Standard error of slope (residual standard deviation), 
sensitivities (RSD, graph), residual analysis, statistical 
tests (vs. quadratic regression). 
Non-significant 
ordinate intercept 
Inclusion of zero in confidence interval of the ordinate 
intercept, magnitude of the intercept (as percent of the 
signal at 100% test concentration). 
Multiple Point 
Calibration 
Linear, Unweighted 
Homogeneity of 
variances® 
Linear function 
/^test of the variances at the lower and upper limits of 
the range. 
Standard error of slope (residual standard deviation), 
sensitivities (RSD, graph), residual analysis, statistical 
tests (vs. quadratic regression). 
Homogeneity of 
variances® 
/^test of the variances at the lower and upper limits of 
the range. 
Linear, Weighted Linear function Standard error of slope (residual standard deviation), 
sensitivities (RSD, graph), residual analysis, statistical 
tests (vs. quadratic regression). 
Non-linear Continuous function Appropriate equation 
100%-method 
(area normalisation 
for impurities) 
For main peak: 
Linear function 
Standard error of slope (residual standard deviation), 
sensitivities (RSD, graph), residual analysis, statistical 
tests (vs. quadratic regression). 
Non-significant 
ordinate intercept 
Inclusion of zero in confidence interval of the ordinate 
intercept, magnitude of the intercept (as percent of the 
signal at 100% test concentration). 
Homogeneity of 
variances® 
/^test of the variances at the lower and upper limits of 
the range. 
For impurities: 
Linear function 
Standard error of slope (residual standard deviation), 
sensitivities (RSD, graph), residual analysis, statistical 
tests (vs. quadratic regression). 
' May be presumed for a limited range (factor 10 - 20). 
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As per the ICH guidelines, the accuracy of an analytical procedure (Table 1.5) 
expresses the closeness of agreement between the value, which is accepted either as a 
conventional true value, or an accepted reference value, and the value found [143]. There are 
different approaches to confirm the accuracy of a method like comparison of the proposed 
method with another one, from the recovery data, by the linearity method etc. The comparison 
of two analytical procedures can be performed using a t-test. It must be verified beforehand, 
whether the scattering of both data sets is of a comparable magnitude (homogeneity of 
variances, F-test). If reference substance is available, the mean obtained with the proposed 
analytical procedure is tested versus the known or declared content. However, the absolute 
magnitude of the difference should also be taken into consideration. Alternatively, an 
acceptable difference can be defined as acceptance criteria, or a statistical equivalence test can 
be applied. For both methods of comparison, it must be taken into consideration that two 
independent analytical procedures most probably differ in their specificity. This might lead to a 
systematic influence on the results. If the effect can be quantified, the means should be 
corrected before performing the statistical comparison. If a correction is not possible, the 
presumptions of the statistical test are violated and the t - test should consequently not be 
performed. 
The lack of interference's between the matrix (placebo) and the analyte, adsorption 
within the equipment, incomplete extraction of the analyte during the sample treatment, 
degradation etc. can be verified by spiking known amounts of the analyte to the matrix 
(placebo). For example, drug substance is spiked to placebo (reconstituted drug product) or 
impurities / degradants are added to drug substance or drug product and are subsequent 
analysed. This should be performed as near as possible to the authentic conditions. Ideally, the 
drug product is prepared with different contents of active ingredient. The least authentic 
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approach would be the addition of standard stock solutions to a placebo solution. 
By spiking at different concentration levels, the recovery can be calculated either at each level 
separately as a percent recovery, or as a linear regression of the found concentration versus 
the added concentration (recovery function). In the case of the percent recovery it can be 
tested, whether the recovery mean differs significantly from the theoretical value 100 % (e.g. 
by inclusion of 100 within the 95% confidence interval). However, the absolute magnitude of 
the difference should also be taken into consideration, especially with respect to impurities in 
low concentration ranges. Alternatively, an acceptable difference to 100% can be defined as 
acceptance criteria, or a statistical equivalence test can be applied. With respect to the 
recovery function, the slope and intercept can be tested versus the theoretical values of 1 and 
0 (by their 95% confidence intervals) or versus acceptable limits for deviation. Due to the 
different weighting effects, the two approaches might lead to different results. The procedure 
should be selected as a function of the quantitation method. The single-point calibration 
represents a normalisation procedure; therefore the percent recovery is better suited. The 
recovery function is indicated if a multiple-point calibration is used. It is absolutely essential 
that the accuracy be validated with the same quantitation method that is used in the control 
test procedure. Recovery deviations from the theoretical values while performing a calibration 
with a drug substance alone may indicate interferences between the analyte and 
placebo/matrix components. In such a case, the calibration should be done with a synthetic 
mixture of placebo and drug substance standard. Such interferences may also be detected by 
the separate determination of linearity for dilutions of the drug substance and for a spiked 
placebo. Both regression lines can be compared statistically or graphically (e.g. by verifying 
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that recovery data are within the prediction interval of the drug substance linearity). The 
accuracy can be established in different ways, using statistical analysis. 
Precision of an analytical procedure expresses the closeness of agreement (degree of 
scatter) between a series of measurements obtained from multiple sampling of the same 
homogeneous sample under the prescribed condition [143]. Precision should be measured 
using homogenous authentic samples. However, if it is not possible or if it is not practical to 
obtain a homogeneous sample, it may be measured using artificially prepared samples or 
sample solutions. Precision must be assessed in several ways: 
Table 1.5. Quantitative approaches to demonstrate accuracy according to ICH. 
Drug substance Application of the analytical procedure to a 
reference material. 
Comparison of the results with those of a 
second well characterised procedure. 
Drug product 
Impurities (quantitative) 
Application of the analytical procedure to 
synthetic mixtures of drug product 
components 
Spiking of analyte to drug product. 
Comparison of the results with those of a 
second well characterised procedure. 
Spiking of the impurity to drug substance or 
product. 
Comparison of the results with those of a 
second well characterised procedure. 
Repeatability, also termed as intra-assay precision, refers to the precision obtained 
under the same operating conditions over a short interval of time by applying the whole 
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analytical procedure to the sample. Repeatability should be assessed using a minimum of 6 
determinations at 100% of the test concentration or a minimum of 9 determinations over the 
range of the procedure (e.g. 3 replicates for each of 3 concentrations). This will provide an 
estimate of the random error of the method. 
Intermediate precision refers to within-laboratory variations, preferably performing a 
method over an extended period of time. The extent of investigation will depend on the 
intended use of the procedure. A typical investigation of Intermediate precision would study 
various parameters that might include analysts, days, equipment, reagents, columns, etc. 
Reproducibility is an estimate of the variation between different laboratories and is 
usually assessed by performing an inter-laboratory (collaborative) study. A study of 
reproducibility is not required as a part of the marketing authorisation dossier. 
Robustness/ruggedness of an analytical method can be defined as "a measure of the 
capacity of analytical procedure to remain unaffected by small, but deliberate variations in 
method parameters and provides an indication of its reliability during normal usage " [ 148]. It 
can also be described as the ability to reproduce the (analytical) method in different 
laboratories or under different circumstances without the occurrence of unexpected differences 
in the obtained result(s), and a robustness test as an experimental set-up to evaluate the 
robustness of a method. Though these two terms have been frequently used as the synonyms 
[149] but sometimes a mutual differentiation have also been made [150], according to which 
the ruggedness is defiried as the degree of reproducibility of the test results obtained under a 
variety of normal test conditions, such as different laboratories, different analysts, different 
instruments, different lots of reagents, different elapsed assay times, different assay 
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temperature, different days, etc. The ICH guidelines also recommend that "one consequence 
of the evaluation of robustness should be that a series of system suitability parameters (e.g. 
resolution tests) is established to ensure that the validity of the analytical procedure is 
maintained whenever used" [\A%]. Deliberate variations in the parameters of a procedure will 
provide an estimate of its reliability in routine use. The extent of robustness studies will depend 
upon the type of method but this evaluation should be considered during the development 
phase. Typical variations might include extraction time, flow rate through a testing device, 
stability of test solutions, etc. 
Statistical treatment of certain validation parameters of common Interest 
In analytical methodology 
Linear regression by least square method; WomdX\s^\:m factor (unweighted linear regression: 
Means: 
X 
Sumofsq ^YS-K " Qyy = YJ^K ^Oi -y)^) 
Qny ''YSK - ^ X X i -y)) 
Residual sum of squares (Qyy) and Residual standard deviai 
Slope (b), standard deviation of slope (st) and Relative confidence interval of the slope (Ob): 
Q 
Q. n 
Q. " ^ -•XX. 
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Intercept (a), standard deviation of intercept (Sa) and Confidence interval of the intercept (CLa; 
upper and lower limits): 
_ + 
« \ # 
Standard error (5^) and Relative standard error of slope ( l ^ ) : 
. J *o 
Coefficient of correlation (r): 
Residuals and %-Difference: 
yW 
Where = experimental >M/alue and y(Xi) = calculated ><-value for the given ^-value. 
Calculation of concentrations with uncertainties: 
Input of jM/alues: Calculation of concentration (y , ) 
Input of /-values: Calculation of signal 
Uncertainty and Relative uncertainty: 
Accuracy 
(1) by comparison and validation procedure: 
- 1 * 
MeanW, ^ = « 1-1 
Confidence interval {CL(x) upper and lower limit), CL{x) = x ± s * ^—^ 
4n 
Variance (5^, Standard deviation (s) and Coefficient of variation {CVo\ RSD), 
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X 
Range [R%], — f i ? 5 L * 1 0 0 
Linearity (overall analysis, unweighted linear regression) 
Comparison with the slope of the 1 st series: 
Limits of the equivalence interval; 
C t r " = 1 0 0 f f^i l ] .S.^Ip.mi+M;-4)1-1 exp - 1 Ci "100. 
6% = Acceptable difference (percentage). 
t(P,f) - Student's /-value for level of statistical confidence /'and degrees of freedom, f=n+q-4. 
Where btj, sbf^ n^j = slope, standard deviation of the slope, and number of values of series 1 
and j, respectively. 
The slopes of series /and /are equivalent, i l - cWq < C i / s C ^ < 
/Ico/rag^ (recovery from linearity): Comparison of the slope with the theoretical value of 1. 
Limits of the Equivalence interval: 
C,=b-\-t{P,n-2) 
6 = acceptable difference (absolute value). 
'JQxi 
t(P,f) = Student's /-value for level of statistical confidence /'and degrees of freedom, f=n-2. 
Sy,Qxx= residual standard deviation, sum of squares. 
The slope is equivalent to the theoretical value of /, if - < C ^ C ^ 1 
Accuracy recovery, comparison to reference): Comparison of the mean with a nominal value. 
Limits of the equivalence interval: 
Cu = T - x + t{P,n-\) 
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T= nominal value (100% or reference value). 
5 = Acceptable difference (absolute value). 
t(P,f) =Student's /-value for level of statistical confidence /'and degrees of freedom, f=n-1. 
Where x, s,n = mean, standard deviation and number of values, respectively. 
/"are equivalent, if n / x 
- dV s C^ s £7 
Accuracy (Comparison to another procedure): Comparison of two means 
(f -
Ci -100-
J V / 
Ctr -100^ 
a - \ 
cxp 
i s^^ * 
1 1 
+ 
'i{P,ni +«3 - 2 ) s ] - l | 
+ «2 - 2 
5 % = Acceptable difference (percentage). 
t{P,fJ = Student's lvalue for level of statistical confidence F and degrees of freedom, 
f=ni+nz-2. 
Where African, variance, and number of values of series 1 and 2, respectively. 
The two means are equivalent, if , ^ ^ ^ i,/ 
Precision (individualseries^. Comparison of the standard deviation with a nominal value. 
Limits for the equivalence interval: 
Cj, =100^ 
s 
T\ 
- i L C c r =100< - 1 
5 % = Acceptable difference (percentage of the standard deviation). 
Ap.f) 
= Chi-squared distribution for level of statistical confidence Por / - f and degrees 
of freedom f=n-1. 
mean, variance, and number of values. 
Experimental and target standard deviation are equivalent, if - i^/o < C^ t^ /o 
Test for Outliers 
With regard to linearity, an outlier is characterised by a significant deviation from the 
regression curve. The 95% prediction interval can be used as a criterion. This interval 
describes the range around the regression function in which a repeated analytical value can be 
expected in 19 out of 20 cases. If the calculation of the 95% prediction interval is performed 
with all values, a possible outlier might have a considerable influence on the calculation (by 
broadening the interval). The suspected value or values can be inactivated manually and a 
second regression is performed. If the deactivated value or values are now outside the 95% 
prediction interval, they can be suspected as being outliers. In the same manner, deviations 
from a linear response performing a linear regression can be detected. However, it must be 
taken into consideration that the prediction interval will be less stringent (broader) as the 
extrapolation increases ("trumpet-shaped"). Most statistical tests and calculations are based 
on the assumption that the experimental values are only influenced by random variability (i.e. 
that they are normally distributed). Data that do not fulfil these assumptions (e.g. due to so 
called "gross errors", weighing, dilution, or by problems with the instrument etc.) will affect the 
results. It is the aim of outlier tests to identify such values in order to eliminate them before 
performing further calculations. However, the problem is especially with a small number of data 
where groupings could easily occur avoiding the incorrect rejection of values belonging to the 
same distribution. Therefore, outlier tests should be applied carefully and only obviously 
deviating values should be eliminated. When an outlier is identified, the absolute magnitude of 
the coefficient of variation (relative standard deviation) must also be considered for evaluation. 
If this parameter (calculated including the suspected "outlier") lies in a normally expected 
range, preferably all values should be retained. The question of systematic effects influencing 
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the values (e.g. degradation or adsorption of the analyte, shifts in the equipment settings, etc.) 
is of more importance. This can be investigated by applying a trend test in which an unweighted 
linear regression is performed using the values in the order of the input (equidistant spacing 
with respect to the x dimension). The 95% confidence interval of the slope is then tested 
against the slope Itself. If a slope can not be detected statistically, the hypothesis of a 
systematical trend can be rejected. 
F- and Mests: 
(i) Mean Mests: 
^>F{PJ\J2) . ^ 
/4est: If Sj with s i > s 2 then significant difference of variances 
exists. F(P, f1, f2) = Fisher's /^^alue for level of statistical confidence P and degrees of 
freedom f j and 4 
If — * j ecmfBi^ ^ ^ ^ p^ jnificant difference of mean exists. 
Where 
/ 
Nominal value Mest.' 
D.. ^ 
If — * > t (P. f ) significant difference to the reference exits. 
^r^eraiee Where / = rij - / and Dj 
t(P, f) - Student's /-value for level of statistical confidence /'and degrees of freedom f. 
and = mean, standard deviation, number of values in validation series. 
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CLASSIFICATION OF DRUGS 
All the drugs according to their chemical nature can be divided into organic and 
inorganic compounds. They can be prepared synthetically (from chemicals) or can be directly 
obtained or reconstituted from the natural sources/products. All the drugs having medicinal 
importance can be broadly divided into two classes. 
Chemical classification: Here the drugs are classified according to their chemical 
structure and properties without taking the pharmacological actions under consideration. In this 
class most of the drugs are having at least an organic substrate, the further classification is 
done in the relevant manner. 
Pharmacological classification: In this class the drugs are divided according to 
their action on the organism/organ (viz. heart, brain, lymphatic system, respiratory system, 
endocrine system, central nervous system etc.). Hence these drugs are named like antianginal, 
narcotics, soporifics, analgesics, diuretics and anaesthetics etc. Further classification of each 
group is done according to the therapeutic/pharmacological specificity with the relevant organ. 
A detailed classification of the gastro-intestinal drugs with respect to their therapeutic 
importance for the treatment of gastric ulcers have been presented in Table 1.6. 
ANTIULCER DRUGS 
Mankind has lived with peptic ulcers since ancient times. Many prominent people have 
suffered from indigestion and ulcers, including the Roman emperor Marcus Aurelius, whose 
death has been, attributed by some to a perforated ulcer. Acid neutralisation was recognised 
as effective treatment more than 12 ceturies ago by Paulus Aeginata, who prescribed a mixture 
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of Samian and Lamnian earths and milk, not unlike the milk-antacid regiments of the mid-
twentieth century. 
The term acid-peptic disorders encompasses a variety of relatively specific medical 
conditions in which injury by gastric acid (and activated pepsin) is thought to play an important 
role. These disorders include gastrooesophageal reflux disease, benign "peptic" ulcers of the 
stomach and duodenum, ulcers secondary to the use of steroidal antiinflammatory drugs and 
ulcers due to the rare Zollinger-Ellison syndrome. It appears that exposure of the involved 
tissue to acid is essential to the development of clinical symptoms in most instances of these 
diseases. Control of gastric acidity is therefore a cornerstone of therapy in these disorders, 
even though these approach may not address the fundamental pathophysiological process. 
The advances in understanding the pathogenesis and In the treatment of acid-peptic 
conditions have occurred, culminating In the discovery of Helicobacter pyroll and proton pump 
inhibitors. We know that eradication of H. pyroll effectively promotes healing of peptic ulcers 
and prevents their recurrence in most cases. Proton pump Inhibitors have become the drugs of 
choice in promoting healing from erosive esophagitis and peptic ulcer disease because of their 
ability to nearly completely suppress acid production. Although several clinical challenges still 
need to be met in this area, it is reasonable to conclude that the battle against the ravages of 
gastric add is finally turning in our favour. 
This thesis deals with the quantitative analysis of certain antiulcer drugs belonging to 
H2 receptor antagonist (famotidine and roxatidine acetate hydochlorlde) and proton pump 
inhibitors (lansoprazole and pantoprazole). 
The H2 receptor antagonists competitively and irreversibly bind H2 receptors on the 
parietal cell, diminishing cytosolic cyclic adenosinemonophospate production and secretion of 
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histamine-stimulated gastric acid. The most prominent effects of Hz receptor antagonists are 
on basal acid secretion; less profound but still significant is suppression of stimulated (feeding, 
gastrin, hypoglycemia, or vagal stimulation) acid production. These agents thus are particularly 
effective in suppressing nocturnal acid secretion. 
Famotidine (C8H15N7O2S3) 
Famotidine is chemically 3-[2-(diaminomethyleneamino)thiazol-4-ylmethylthio]-N-
sulfamoylpropionamidine is a histamine Ha receptor antagonist. Drug should be stored in a 
well-closed container and protected from light. Famotidine tablets contain not less than 90% 
and not more than 110% of the labelled amount of famotidine. 
NSO2NH2 
H2Nv n CH2-S-CH2.CH2-C^ 
NH2 
Hzi ^ ^ " 
Structure I 
The drug is used in conditions where inhibition of gastric acid secretion may be 
beneficial, such as gastric acid and duodenal ulcers. The drug does not appear to bind to 
microsomal cytochrome P450. Famotidine is rapidly but incompletely absorbed from the 
gastrointestinal tact with peak concentration in plasma occurring about 2 hours after 
administration by mouth, 
Roxatidine acetate hydrochlor ide ( C17H26N2O3 CzHzO.HCI) 
Roxatidine acetate hydrochloride is chemically N-{3-[(a-piperidino-m-
tolyl)oxy]propyl}glycolamide acetate monohydrochloride.The drug is a histamine Hz receptor 
antagonist. The drug is rapidly and almost completely absorbed from the gastrointestinal tract 
with peak concentration in plasma occuring about 1 to 3 hours after administration by mouth. It 
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is rapidly hydrolysed to the active desacetyl metabolite, roxatidine, by esterases in the liver, 
small intestine, and serum. Roxatidine does not appear to effect cytochrome P450, and 
therefore is considered to have little effect on metabolism of other drugs. Over 90% of a dose 
is excreted in urine as roxatidine and other metabolites. 
Structure II 
The proton pump inhibitors (PPI) dose-dependently inhibit basal and stimulated gastric 
acid secretion. Under acidic conditions in the parietal cell, the parent compound is protonated 
and converted to active metabolites, which react covalently with H+/K"^ -ATPase (the proton 
pump). A sulfahydryl bond Is formed that non-competitively and irreversibly inhibits activity of 
the enzyme. Full restoration of acid secretion after discontinuing the PPI takes about 3 to 5 
days because PPIs are concentrated and activated in acidified compartments, they inhibit only 
those proton pumps that are actively secreting acid. 
Lansoprazole (C16H14F3N3O2S) 
Lansoprazole is a substituted bezimidazole and chemically is 2-({3-Methyl-4-(2,2,2-
trifluroethoxy)-2-pyridyl)methyl}sulphinylbezimidazole. It is used in the treatment of peptic 
ulcer disease and in other conditions where inhibition of gastric acid secretion may be 
beneficial. Lansoprazole is also used in the treatment of pathological hypersecretory states 
such as Zollinger-Ellison syndrome. Lansoprazole is thought to be a week inducer of hepatic 
cytochrome P450, and may effect the pharmacokinetics of other drugs, which are metabolized 
by this system. Lansoprazole may be combined with antibacterials in triple therapy regimens 
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for the elimination of Helicobactor pylori. Lansoprazole is rapidly absorbed after oral 
administration with peak plasma concentration achieved about 1.5 hours after a dose by 
OCH2CF3 
Structure III 
mouth. Drug is extensively metabolized in liver and excreted primarily in faeces via the bile; only 
about 15 to 30% of a dose is excreted in urine. 
Pantoprazole (C16H15F2N3O4S) 
It is chemically 5-difluomethoxybezimidazole-2-yl 3,4- dimethoxy-2-pyridylmethyl 
sulphoxide. Pantoprazole, a substituted benzimidazole derivative, is an irreversible proton 
pump inhibitor, which has been developed for the treatment of acid related gastrointestinal 
disorders. 
0CH3 
Structure IV 
In acidic environment pantoprazole is rapidly converted to active species, a cationic 
cyclic sulphonamide, which binds covalently to cysteine residues on the luminal (acidic) surface 
of H+, K"^ -ATPase to form a mixed disulphide, thereby causing irreversible inhibition of gastric 
proton pump function. 
Pantoprazole did not appear to influence endocrine function in healthy volunteers 
during short-term administration. The drug has lower affinity for hepatic cytochrome P 450 and 
shows no clinically relevant pharmacokinetic or pharmacodynamic interaction at therapeutic 
doses with a wide range of drug substrates for this isoenzyme system. 
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Introduction 
Famotidine, 3-[2-(diaminomethyleneamino) tliiazol-4-ylmetliylthio]-N-
sulphamoylpropionamidine, is relatively a new histamine Ha receptor antagonist with actions 
and uses similar to those of cimetidine. It is widely used for the treatment of gastro-intestinal 
disorders, such as aspiration syndrome, dyspepsia, gastro-oesophageal reflux disease, peptic 
ulcer and hyperacid secretory conditions such as Zollinger-Ellison syndrome [1]. Therapeutic 
trials have shown that famotidine is twenty times more effective than cimetidine in inhibiting 
gastric acid secretion in humans [2]. The drug is official in European Pharmacopoeia [3] and 
United States [4], which described the potentiometric titration and HPLC methods for assay of 
famotidine In pharmaceutical formulations. Thin layer chromatographic [3, 4] and high 
performance thin layer chromatographic methods [5] have been reported for purity control of 
famotidine. 
A review of literature revealed that several HPLC methods have been described for the 
determination of famotidine in biological fluids and pharmaceutical formulations [6-16]. These 
methods have enough sensitivity to determine lower concentration of the drug and hence, it is 
justified to use them for assay of such a lower concentration in biological fluids. However, it is 
always required to develop analytical methods using low cost techniques. UV-visible 
spectrophotometry is still considered a convenient and economical technique for routine 
analysis of the drug in pharmaceutical formulations in third world countries. 
The famotidine was determined spectrophotometrically [17] based on the reaction of 
drug with 1, 4-benzoquinone at pH 5.2. Beer's law was obeyed in the concentration range of 
4 0 - 1 6 0 |j.g mL~' at 502 nm. Another spectrophotometric method [18] was described which 
involved the interaction of famotidine with p-chloranilic acid in acetonitrile and subsequen
60 
measurement at 521 nm. The first derivative value of interaction product with p-chloranilic acid 
was also measured at 323 nm. Several other spectrophotometric methods [19] have also been 
reported in the literature based on the charge transfer complexation with chloranil, 2, 3-
dichloro 5, 6-dicyano 1, 4-benzoquinone and dichloronitrophenol and absorbance 
measurements were made at 458, 460 and 425 nm, respectively. Extractive 
spectrophotometric methods [20, 21] for its determination have been discussed which 
described extractable 1:1 Ion-pair complex between famotidine and each of bromocresol green 
(BC6) and bromothymol blue (BTB). Beer's law was obeyed over the concentration ranges of 
2.0 - 23.6 and 0.7 - 8.1 ng mL' with molar absorptivities of 5.0x10^ and 1.2x10^ L moh' cm"' 
for famotidine-BCG and famotidine-BTB, respectively. The detection limits were found to be 2.0 
and 0.7 ng mL~' for bromocresol green and bromothymol blue, respectively. A stability 
indicating method was developed based on measuring the peak height of the second derivative 
at 304 nm [22]. The drug content in pharmaceuticals was also estimated [23] by reaction with 
sodium nitorprusside in alkaline medium resulting in the formation of red coloured complex, 
which absorbed maximally at 498 nm. Famotidine was determined in tablets by difference 
spectrophotometric and quadratic polynomial coefficient methods [24, 25]. 
A differential pulse voltammetric method [26] was suggested based on its 
electrochemical oxidation at a glassy carbon or platinum electrode. It was also determined by 
potentiometric titration [27] with a solution of palladium (II) chloride at pH 3.6 using a silver 
electrode. 
This chapter is divided into two sections, namely 
[A] Kinetic spectrophotometric detenninatlon of famotidine in commercial dosage forms. 
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[B] Application of ninhydrin to spectrophotometric determination of famotidine in drug 
formulations. 
The section A of this chapter deals with a kinetically based spectrophotometric method 
for determination of famotidine in pharmaceutical formulations. The method involves oxidation 
of the drug with alkaline potassium permanganate at room temperature and subsequent 
measurement of the absorbance at 610 nm. 
The section B describes the spectrophotometric method for the determination of 
famotidine based on the reaction of amino group of the drug with ninhydrin in N, N'-
dimethylformamide medium. 
TCCwetCcy ^ e<:tr6p}uyt(yvYietrvo 
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Experimental 
^paratus 
Spectronic 20D+ Spectrophotometer (Milton Roy, USA) was used to measure the 
absorbance. 
Materials and reagents 
Famotidine was kindly provided by Wockhardt Ltd., India, and was used as received. 
Pharmaceutical preparations of famotidine, such as Topcid (Torrent Pharmaceuticals Ltd.), 
Famocid (Sun Pharmaceutical Industries Ltd.), Famotin (USV Ltd.) and Facid (Intas Labs Pvt. 
Ltd.), were purchased from local market. All other reagents used were of analytical grade. 
A standard solution of famotidine (1 mg mL"^ ) was prepared by dissolving 100 mg in 
0.5 mL of 1M NaOH, and further diluted to 100 mL with doubly distilled water. A working 
solution of famotidine (0.1 mg mL^) was prepared by the dilution of 2.5 mL of the standard 
solution to 25 mL with doubly distilled water. Aqueous solutions of sodium hydroxide (1M) and 
potassium permanganate 0.01 M were prepared in doubly distilled water. 
Procedure for determination 
Initial rate methodNi\(\m\s of 0.01 M KMn04 solution (1.0 mL) and 1M NaOH solutions (1.5 
mL) were transferred into a 10 mL volumetric flask. An accurate volume of the working solution 
of famotidine (0.2 - 1.0 mL) was added and diluted to volume with doubly distilled water. The 
contents of the mixture were shaken well and immediately transferred to a spectrophotometric 
cell. The absorbance was recorded as a function of time at 610 nm against a reagent blank at 
room temperature. The initial rate of the reaction at different concentrations was obtained from 
the slope of the tangent to the absorbance time curve. 
A calibration graph was constructed by plotting the logarithm of the initial rate of the 
reaction vs. the logarithm of the molar concentration of famotidine. In the second procedure, 
the absorbance measured at a fixed time of 12 min. was plotted against the final concentration 
of famotidine. The content of the drug was calculated either from the calibration graphs (Fig. 
2.1 and 2.2) or regression equations. 
Procedure for the determination of Famotidine in Pharmaceutical formulations 
Ten tablets were accurately weighed and powdered. A portion equivalent to 50 mg of 
famotidine was extracted with methanol by shaking and filtered on whatman No. 42 filter paper. 
V ^ 
The filtrate and washings were evaporated to dryness. The residue was dissolved in a minimum 
volume of 1M NaOH and diluted according to need. The assay of famotidine was completed by 
following the recommended procedures. 
Results and Discussion 
In an alkaline medium, potassium permanganate oxidizes famotidine, resulting in the 
formation of manganate ion, which showed an absorption peak at 610 nm. Because the 
intensity of the colour increased with time, a kinetically based method was elaborated for the 
determination of famotidine in dosage forms. The various experimental parameters affecting 
the formation of the reaction product were optimised. 
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Effect of the KMn04 concentration 
To study the effect of the KMn04 concentration, aliquots of famotidine containing 
100 |ig mL^ were transferred into a series of 10 mL volumetric flasks, followed by varying 
volumes of 0.01 M KMn04 (0.1 -1.0 mL) and 1.5 mL of 1M NaOH solutions. The absorbance at 
610 nm was measured at a fixed time of 16 min. It is apparent from Fig. 2.3 that the 
absorbance increased with increasing volume of the KMn04 solution, and became constant at 
0.8 mL. Thus, the adoption of 1.0 mL of 0.01 M KMn04 in the final solution proved to be 
adequate for the maximum concentration of famotidine used in the calibration curve. 
Effect of the NaOH concentration 
The influence of the NaOH concentration on the formation of Mn04 "^ was examined 
critically. It was observed (Fig. 2.4) that the maximum absorbance of the reactant solution was 
obtained with 1.2 mL of 1M NaOH. Hence, an optimum value of 1.5 mL was used throughout 
the experiment. 
Stoichbmetery 
The combining ratio between potassium permanganate and famotidine was established 
by the limiting logarithmic method [28] using two sets of experiments. In the first set, the 
famotidine concentration was varied while keeping a constant KMn04 concentration; in the 
second set, the KMn04 concentration was varied while keeping a constant concentration of 
famotidine. The logarithms of the absorbance were plotted against the logarithms of the varied 
concentration (Fig. 2.5). The combining molar ratio was obtained from the slope of the curves, 
and was found to be 1:1 famotidine/KMn04. 
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The famotidine contains a thio ether linkage, which has an ability to oxidize to the 
corresponding sulphoxide. Based on literature background and our experimental findings, the 
reaction mechanism is proposed and given in Scheme 1.1. 
Initial rate method 
The initial rates of the reaction were determined by measuring the slopes of the initial 
tangents to the absorbance time curves (Fig. 2.6). The order with respect to permanganate 
was estimated by studying the reaction at different initial concentrations of KMn04 with a fixed 
famotidine concentration. A plot of the initial rate, dA/dt, against the initial absorbance was 
linear while passing through the origin. This indicated that the order of the reaction with 
respect to permanganate at the start was one. The order with respect to famotidine was 
obtained by plotting the log initial rate of the reaction vs. the log molar concentration of 
famotidine, and was found to be unity. 
Under the optimised conditions, the concentration of famotidine was determined using 
an excess of a KMn04 and NaOH solution with respect to the initial concentration of famotidine. 
As a consequence, a pseudo zero-order condition was obtained with respect to their 
concentrations. However, the initial rate of the reaction would follow a pseudo first-order 
equation, 
Rate = AA/At = K' 
where C is the concentration of famotidine. The above equation is transformed into logarithmic 
equation as 
93 
H2N . . 
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HjN / \ 
NSO2NH2 y\ 
CH2-S-CH2.CH2-C + 2Mn04 "+ 20H" \ 
NH, 
H,N 
CH2-S-CH2.CH2-C, 
/ 
\ 
NSO2NH2 
+ 2Mn04^"+ H2O 
NH, 
Scheme 1.1 
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Fig. 2.6 Absorbance vs. time graph for tlie reaction between 
famotidine and KMn04, siiowing the dependence of the reaction on 
famotidine concentration 
{•) 5.92x10-6 M; (•) 1.77x10-5 M and 2.96x10-^M. 
log (rate) =log AA/At = log K' + n log C. 
A regression of the log rate versus log C gave a regression equation, 
log (rate) = 3.212 + 1.021 logC, 
with a correlation coefficient (r) of 0.9971. 
The regression equation also confirmed that the reaction is first order with respect to 
the famotidine concentration. The calibration curve was found to be linear over the range 2 -
10 jig m L l The confidence limit for the intercept value at the 95% confidence level was 
calculated using the relation a ± /Sa, [29] and was found to be 3.212 + 0.0387, which pointed 
towards a high reproducibility of the method. The detection limit [30] percent relative standard 
deviation, standard analytical error and variance were found to be 0.0336 ng mL•^ 1.68%, 
0.0319 and 3.76x10"^, respectively. The small value of the variance confirmed the negligible 
scattering of the calibration data points around the line of the regression. 
Fixed-time method 
At a preselected fixed time, the absorbance of a green-coloured solution containing 
varying amounts of famotidine was measured at 610 nm. Calibration graphs were constructed 
by plotting the absorbance against the initial concentration of famotidine at a fixed time of 
4,8,12 and 16 min. The calibration equations, correlation coefficient, detection limit, variance 
and molar absorptivity are given in Table 2.1, It was observed that the most acceptable values 
of the relative standard deviation and the intercept were obtained at a fixed time of 12 min.. 
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and therefore were considered to be the most suitable time interval for measurements under 
this condition. The calibration graph was linear over the concentration range of 1 - 8 fig mL', 
A strong correlation also existed between the slope and the intercept of the calibration 
line (at a fixed time of 12 min.). This was established by drawing a joint confidence region (Fig. 
2.7) at the 95% confidence level following the method of Mandel and Linnig [31]. It is evident 
from the figure that the point for which the intercept is zero fell well within the ellipse, thus 
confirming no significant difference from zero. 
The validity of the proposed methods was tested by adding a fixed amount of pure 
drug to preanalysed dosage forms. The results obtained from the investigations are 
summarized in Tables 2.2 and 2.3 respectively, which indicated that the common additives and 
excipients did not interfere with the determination. 
The initial-rate method and fixed-time method were applied to the determination of 
famotidine in commercial dosage forms. The concentration of the drug was computed from the 
corresponding regression equations. The results (Tables 2.4 and 2.5) obtained by the 
proposed method, were compared statistically with that of a reference method [7], revealing 
the fact that there is no significant difference in the performance of the methods regarding 
accuracy and precision. 
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Table 2.2 
Determination of famotidine in pharmaceutical preparations by the initial-rate method using the 
standard addition technique 
Formulation® Amount 
added 
(Hg mL-i) 
Amount 
taken 
(MQ mL-') 
Total amount 
found 
(ngmL-1) 
Recovery, 
(%) 
SAE" RSD, 
(%) 
Topcid 40 2 2 4.01 100.40 0.0199 1.21 
4 2 6.01 100.11 0.0124 0.50 
3 5 8.01 100.06 0.0579 1.77 
Famocid 40 2 2 4.01 100.18 0.0247 1.51 
4 2 5.99 99.90 0.0313 1.27 
3 5 7.95 99.47 0.0558 1.72 
Famotin 40 2 2 3.96 99.20 0.0230 1.42 
4 2 5.98 99.82 0.0304 1.24 
3 5 8.02 100.34 0.0443 1.35 
Facid 40 2 2 3.96 99.09 0.0199 1.23 
4 2 6.01 100.26 0.0156 0.63 
3 5 7.94 99.36 0.0544 1.67 
®Six independent analyses. 
''Standard analytical error. 
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Table 2.3 
Determination of famotidine in pharmaceutical preparations by the fixed-time method using the 
standard addition technique 
Formulation® Amount Amount Total Recovery, SAP RSD, 
added taken amount (%) (%) 
(Hg mL-1) (^ig mL-1) found 
(Hg mL-1) 
Topcid 40 1 1 1.98 99.38 0.0133 1.64 
2 4 6.01 100.12 0.0135 0.55 
3 5 7.96 99.52 0.0195 0.60 
Famocid 40 1 1 1.97 98.85 0.0112 1.39 
2 4 5.99 99.95 0.0139 0.56 
3 5 7.97 99.62 0.0141 0.43 
Famotin 40 1 1 1.96 98.05 0.0139 1.74 
2 4 6.01 100.17 0.0192 0.78 
3 5 7.96 99.52 0.0231 0.71 
Facid 40 1 1 1.96 98.45 0.0147 1.82 
2 4 5.99 99.91 0.0152 0.62 
3 5 7.96 99.56 0.0174 0.53 
®Six independent analyses. 
''Standard analytical error. 
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Table 2.4 
Determinations of famotidine in commercial tablets by the initial-rate method and a reference 
method 
Formulation Proposed method Reference method 
Recovery,® RSD, Recovery," RSD, tal^  fcf 
(%) (%) (%) (%) 
Topcid 40 100.32 0.96 100.07 0.50 0.517 3.610 
Famocid 40 99.61 0.73 99.78 0.45 0.485 2.576 
Famotin 40 100.69 1.41 100.03 0.55 1.251 4.335 
Facid 40 99.48 0.78 99.85 0.35 1.064 4.857 
^Average of six independent analyses. 
Value at 95% confidence level is 1.812. 
Value at 95% confidence level is 5.05. 
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Table 2.5 
Determination of famotidine in commercial tablets by the fixed-time method and a reference 
method 
Formulation Proposed method Reference method 
Recovery,® RSD, Recovery,® RSD, 
(%) (%) (%) (%) 
Topcid 40 99.97 1.02 99.71 0.71 0.528 2.078 
Famocid 40 100.19 1.19 100.00 0.54 0.357 4.724 
Famotin 40 100.08 0.91 99.42 0.45 1.592 4.184 
Facid 40 100.45 0.97 100.14 0.65 1.651 2.231 
'Average of six independent analyses. 
^t- value at 95% confidence level is 1.812. 
value at 95% confidence level is 5.05. 
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Experimental 
Apparatus 
A!! spectrophotometric measurements were carried out using a spectronic 20D+ 
spectrophotometer (Milton Roy, USA). A water bath shaker (NSW 133, India) was used to control 
the heating temperature. 
Materials and reagents 
All reagents used were of analytical reagent grade. A 0.1% famotidine (Wockhardt India 
Ltd.) solution was prepared in N, N'-dimethylformamide (DMF) and further diluted according to the 
need with DMF. 
A 0.06 M ninhydrin (E. Merck) solution was also prepared in DMF. 
Procedure for Calibration Curve 
Aliquots of 0.10 mL to 0.60 mL famotidine standard solution (0.25 mg mL') were pipetted 
into a series of boiling test tubes. To each test tube 0.7 mL of ninhydrin solution was added, mixed 
well and heated on a water bath at 100 ± r C for 5 minutes. After heating the solution, tubes were 
cooled to room temperature. The content of the tube was transferred to a 5 mL volumetric flask 
and diluting to volume with DMF. The absorbance was measured at 590 nm against reagent blank 
treated similarly. The concentration of famotidine was calculated either from calibration graph 
(Fig.2.8) or regression equation. 
Procedure for the assay of famotidine in pharmaceutical preparations 
Ten tablets were accurately weighed and powdered. A portion equivalent to 50 mg 
famotidine was stirred with 20 mL DMF and let stand for 10 minutes. The residue was filtered on 
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Fig. 2.8 Calibration curve for determination of famotidine 
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Whatman No. 42 filter paper and washed with DMF. The filtrate and washings were diluted to 
volume in a 50 mL volumetric flask. A suitable volume of this solution was further diluted to give a 
final concentration of 0.25 mg mL'. An aliquot of this solution was analyzed for famotidine 
following the procedure described for the calibration curve. 
Results and Discussion 
The possible use of ninhydrin for the detection and quantitative estimation of amino acids 
and imino acids depends on the formation of Ruhemann purple [33]. It was reported that in 
alkaline medium ninhydrin is converted to o-carboxyphenylglyoxal, which would reduce ninhydrin to 
2-hydroxyindan-1, 3-dione. The primary amino group of famotidine reacted with 2-hydroxyindan-1, 
3-dione in DMF to form the amino compound, which condensed with ninhydrin to give 
diketohydrindylidene-diketohydrindamine (II). 
(11) 
This compound (II) further interacts with amino group of the drug resulting in the 
formation of a blue coloured product, which absorbed maximally at 590 nm. 
The different experimental parameters influencing the intensity of the developed colour 
were extensively investigated to determine the optimal conditions for the assay procedure. All 
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conditions studied were optimised in DMF medium. The optimum reaction time was determined by 
heating the reaction mixture on water bath at 100 ±rC. It is apparent from Fig. 2.9 that complete 
colour development was attained after 4 minutes of heating and remained constant up to 10 
minutes. Therefore, the optimum heating time was fixed at 5 minutes throughout the experiment. 
The effect of ninhydrin concentration on the colour development was investigated. For this 
purpose, different volumes of 0.06 M ninhydrin (0.1 - 1.0 mL) were added to a fixed amount of 
famotidine (25 |ig mL"^ ). The results are presented in Fig. 2.10, which showed that the highest 
and most stable absorbance was obtained with 0.6 mL, beyond which the absorbance became 
constant. A 0.7 mL of the reagent, therefore, was used as an optimum value for colour 
development. 
Analytical data 
In the above established working conditions, the main figures of merit of the proposed 
procedure for determination of famotidine have been established. The calibration graph obtained 
by plotting absorbance at 590 nm against famotidine concentration was found to be linear over 
Beer's law range given in the Table 2.6. The molar absorptivity, detection limit [30],variance, slope, 
intercept, correlation coefficient and linearity obtained by least squares treatment of the results are 
also given in Table 2.6. High value of correlation coefficient confirms the excellent linearity of the 
calibration curve. The value of detection limit and variance speak of good sensitivity of the 
proposed method and negligible scatter of the calibration data around the line of regression. The 
value of intercept is 6.00x10"^ and hence it is required to judge if the intercept is significantly 
different from zero. This has been demonstrated by drawing a joint confidence region for slope and 
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the coloured product (drug = 25 |ig mL"^) 
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Table 2.6 
Optical characteristics and statistical data for the regression equation 
K.3X (nm) 
Beer's law limit {|xg 
Molar absorptivity (L rtiof^ cm"') 
Sandell's sensitivity (ng mL"' per 0.001 A) 
Regression equation" 
Intercept (a) 
Slope (b) 
/Sb^ 
Correlation Coefficient (y) 
Variance [Sg^ 
Linearity 
Detection limit (fig mL"') 
590 
5-30 
6.99x103 
4.83x10"2 
A = 0.006 + 0.0205 C 
6.00x10~2 
3.11 x10"3 
2.05x10~2 
1.49x10"" 
0.9999 
2.69x10"^ 
0.3415 
0.16 
® A = a + bC where C is the concentration in ^g mL"'. 
'' Confidence interval of the intercept at 95% confidence level. 
Confidence interval of the slope at 95% confidence level. 
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intercept following the method of Mandel and Linnig [31, 32] which is an ellipse having the point of 
best fit as its centre. It is evident from Fig. 2.11 that points for which intercept is zero fell well 
within the ellipse. Therefore, it is concluded that the intercept is not significantly different from zero 
and the proposed method is free from constant error independent of the famotidine concentration. 
The absolute error, Sc, in the determination of a given concentration of famotidine was 
calculated by statistical analysis of regression equation [32]. Fig. 2.12 shows a graph of Sc vs. 
concentration of famotidine. It is apparent from the figure that the error is minimum for a 
concentration of about 17 |ig mL^ of famotidine. 
Reproducibility was measured for a series of ten Independent determinations at two 
concentration levels. The percent relative standard deviation and standard analytical error (SAE) 
were found to be 0.94%, 0.059 and 0.60%, 0.057 for the determination of 20 and 30 ^ig mL' of 
famotidine, respectively. 
The validity of the present method was tested by standard addition method. For this 
purpose, solutions containing three different concentrations of famotidine were prepared by adding 
a known amount of pure drug to the preanalysed commercial dosage forms and determined in six 
replicates. The results are summarized in Table 2.7, which can be considered to be very 
satisfactory. The common excipients present in tablet formulations did not interfere in the 
determination of famotidine. 
The commercial tablets were successfully analysed for famotidine content by the proposed 
and reference methods [23]. The results (Table 2.8) obtained by both the methods were 
compared statistically. The calculated Student's t- and f- values did not exceed the theoretical 
91 
c n 
o 
g "lO 
oi O) I 
<u 
Q . 
(U 
•T3 C nJ 
t/1 0) 
g "cn 
a O) (J c <u •O 
s 
c 
"o 
t\J 
o> 
Oh <D 
a (D 
92 
rsi 
O 
10.0-
9 . 8 -
9 . 6 -
9 . 4 -
9 . 2 -
9 . 0 -
8 . 8 -
m 
8 . 6 -
5 
T " 
10 
T " 
15 
- r -
20 25 30 
C o n c e n t r a t i o n ( |ag m L ' ) 
Fig. 2.12 Errors (Sc) in tfie determination of the concentration of famotidine 
Table 2.7 
Determination of famotidine in pharmaceutical preparations by standard addition method 
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Preparation ® Amount 
taken 
( M mL'i) 
Amount 
added 
(ng mL~i) 
Total amount 
found 
(Hg mL"') 
Recovery {%) SAEb RSD (%) 
Topcid 40 10 10 19.66 98.33 0.0659 0.82 
10 15 25.08 100.32 0.0319 0.32 
20 10 29.94 99.81 0.0444 0.36 
Famocid 40 10 10 19.68 98.41 0.0393 0.49 
10 15 25.008 100.03 0.0498 0.48 
20 10 29.96 99.89 0.0498 0.40 
Famotin 40 10 10 19.85 99.26 0.0630 0.77 
10 15 24.98 99.93 0.0526 0.51 
20 10 29.86 99.53 0.0426 0.34 
Famonite 40 10 10 19.92 99.63 0.0535 0.67 
10 15 24.97 99.90 0.0356 0.34 
20 10 29.91 99.70 0.0609 0.49 
Facid 40 10 10 19.91 99.59 0.0709 0.87 
10 15 24.89 99.57 0.0430 0.42 
20 10 29.78 99.29 0.0674 0.55 
® Six independent analyses. 
^ Standard analytical error. 
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Table 2.8 
Determination of famotidine in commercial tablets by the proposed and reference methods 
Formulation Proposed Method Reference Method fcal^  
Recoveiy® RSD Recovery® RSD 
{%) (%) (%) (%) 
Topcid 40 99.70 0.52 99.73 0.30 0.166 2.973 
Famocid 40 100.14 0.65 100.04 0.38 0.430 2.937 
Famotin 40 100.09 0.68 99.86 0.46 0.875 2.193 
Famonite 40 100.14 0.66 100.04 0.38 0.411 3.021 
Facid 40 100.00 0.71 99.91 0.49 0.668 2.126 
"Average of ten independent analyses. 
I" t- value at 95% confidence level is 1.734 [34 
' F- value at 95% confidence level is 3.18 [34]. 
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ones at 95% confidence level, which confirms the absence of any difference between the methods, 
compared. 
The proposed method is favourably compared with other existing spectrophotometric 
methods in terms of molar absorptivity and Beer's law limit (Table 2.9). It is evident from Table 
2.9 that present method is more sensitive (e = 6.99x10^ L mol"' cm"') as compared to other 
reported methods except the method using BTB as ion pair formation reagent. However, the 
Beer's law limit of the proposed method is quite reasonable for the assay of famotidine in 
pharmaceutical dosage forms with low RSD (0.60 - 0.94%) in comparison to the methods involving 
extractable ion pair complexes [20]. Moreover, the present method is fast and directly applicable 
to the drug sample without prior separation or treatment. 
Table 2.9 
Comparison of the proposed method with other existing spectrophotometric methods 
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Reagent m^iax Beer's law limit Molar absorptivity RSD References 
(nm) (ng mL-') (L moP' cm"') (%) 
Sodium nitroprusside 498 5-50 5.90x102 0.15 [23] 
Chloranil 458 50-500 0.67x10^ -
p-chloranilic acid 521 25-240 - <2.0 [18] 
1,4-benzoquinone 502 40-160 - - [17] 
DDQ® 460 40-450 0.82x10^ - [19] 
DCNP" 425 10-100 3.70x103 - [19] 
BCG' 420 2 - 23.5 5.00x10^ 1.6-3.4 [20] 
BTB" 420 0.7-8.1 1.20x10^ 1.8-3.1 [20] 
Methanol 288 5-15 - - [25] 
Ninhydrin 590 5-30 6.99x10^ 0.60-0.94 this worl< 
D^DQ = 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone. 
''DCNP = 2,4-Dichloro-6-nitrophenol. 
'^BCG = Bromocresol green. 
•'BTB = Bromothymol blue. 
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Introduction 
Roxatidine acetate hydrochloride (RAH) is chemically N- {3-[(a-piperidino-m-tolyl) 
oxy] propyl} glycolamide acetate monohydrochloride. It is histamine H2 receptor antagonist and 
listed in Martindale, The Extra Pharmacopoeia [1]. The drug is recommended for the 
management of benign and post operative ulcer, as it does not appear to effect cytochrome 
P450 and therefore considered to have little effect on metabolism of other drugs [2]. It is 
completely absorbed from gastro intestinal tract and over 90 percent of a dose is excreted in 
the urine as roxatidine and other metabolites [3]. Because of these important pharmacological 
responses, development of sensitive and accurate methods for the determination of RAH is 
required. 
Literature survey reveals that few reversed-phase high performance liquid 
chromatographic methods [4, 5] have been reported to quantify RAH in bulk and dosage 
forms. Dimov and Ivanov [6] developed a high performance liquid chromatographic method for 
routine control of the synthesis of roxatidine using reversed phase RP-18 and RP-2 columns. 
The analysis of RAH was also carried out using thin layer chromatography [7]. The UV-
derivative spectrophotometric methods [8] have been suggested for the assay of the cited 
drug in human serum and urine. In serum the analyte is quantified after a solid phase 
extraction whereas in urine it is determined after extraction with 2-methylbutanol. 
2,3-Dichloro 5,6-dicyano 1,4-benzoquinone (DDQ) and p-chloranllic acid are examples 
of K acceptors and have numerous applications as analytical reagents, They have been used 
for the spectrophotometric determination of drugs in pharmaceutical formulations [9-15]. 
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This chapter describes two sensitive, fast, simple and economical methods for 
determination of RAH in pure and dosage forms. Both the methods are based on the charge 
transfer complexation reaction of RAH with DDQ and p-chloranilic acid. 
Experimental 
Apparatus 
A spectronic 20 D+ spectrophotometer (Milton Roy, USA) and Shimadzu, Model No. 
1601 UV-visible spectrophotometer were used to measure absorbance in the visible and UV 
regions, respectively. 
Materials and reagents 
Roxatidine acetate hydrochloride was kindly provided by Aventis Pharma Ltd., India, 
and was used as received. Two different pharmaceutical preparations of RAH such as Rotane 
(Hoest Marrion Roussel) and Zorpex (Stancare Division) were purchased from local market. All 
other reagents used were of analytical reagent grade. 
Standard solutions 
i. 0.2% w/v p-chloranilic acid solution in 1,4-dioxane. 
ii. 0.2% w/v DDQ solution in acetonitrile. 
iii. 0.6M aqueous sodium carbonate solution. 
iv. 1 mg mL^ standard solution of roxatidine acetate hydrochloride in chloroform. 
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Recommended Procedures 
Preparation of roxatidine base solution 
In a 125 mL separatory funnel, 25 mL of 1 mg mL'^  RAH standard solution prepared in 
chloroform was transferred followed by 50 mL of 0.6M aqueous sodium carbonate solution. 
The contents of the separating funnel were mixed well and shaken for 3 min. Two phases were 
allowed to separate and the chloroform layer was dried over anhydrous sodium sulphate. 
Procedure for determination 
f^ethodA 
Aliquots of roxatidine base solution corresponding to 5 - 65 [xg mL-^  were transferred 
into a series of 5 mL volumetric flasks. 1.5 mL of 0.2% DDQ solution was added to each flask 
and diluted to volume with acetonitrile. Absorbance was measured after 3 min. of mixing at 530 
nm against the reagent blank prepared simultaneously. 
f^ethodB 
Into a series of 5 mL volumetric flasks, volumes of roxatidine base solution equivalent 
to 0.05 - 1.30 mg of the drug were transferred. To each flask, 0.7 mL of 0.2% p-chloranilic 
acid was added and brought up to the volume with chloroform. The colour developed was 
measured at 530 nm against the reagent blank. 
The amount of the drug is computed either from calibration graphs (Fig. 3.1 and 3.2) 
or regression equations. 
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Fig 3.1 Calibration curve for determination of RAH using method A 
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Fig 3.2 Calibration curve for determination of RAH using 
metliod B 
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Analysis of pharmaceutical formulations 
Ten tablets were accurately weighed and finely powdered. The amount of powder 
equivalent to 100 mg RAH was extracted into sufficient volume of chloroform with shaking. The 
residue was filtered on Whatman filter paper No.42 and the filtrate was diluted to 100 mL with 
chloroform. The solution of roxatidine base was prepared as discussed under the head 
"preparation of roxatidine base solution" above and the drug was analysed following the 
recommended procedures using DDQ and p-chloranilic acid as reagents. 
UV reference method 
For reference method, a standard solution of the drug (1 mg mL') was prepared in 
water. The absorbance of the solution was measured at 276 nm and Beer's law was obeyed in 
the concentration range of 5 - 90 [ ig mL"'. The amount of the drug was calculated 
from the Beer-Lambert's plot. 
Results and discussion 
The optimum conditions for the development of methods A and B were established by 
varying the concentration of reagent at a time and keeping the fixed drug concentration and 
observing the effect produced on the absorbance of the coloured species. 
In method A, the only variable is the concentration of DDQ since reaction gets 
stabilized within 3 minutes. To study the effect of the concentration of DDQ, varying volume of 
0.2% reagent was mixed with 50 ng mL ' of drug in a 5 mL volumetric flask and 
diluted to volume with acetonitrile. It was found that (Fig. 3.3) 1.2 mL of reagent 
yielded the highest absorbance; above this volume the absorbance remains 
constant. A volume of 1.5 mL was, therefore, used in all further measurements. 
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Fig 3.3 Effect of the volume of 0.2% DDQ on the absorbance 
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To establish the optimum experimental conditions for method B, the drug 
(200 |ig mL^) was allowed to react with varying volumes of 0.2% p-chloranilic acid. The 
maximum absorbance was obtained with 0.5 mL of the reagent (Fig. 3.4); further addition 
caused no change in absorbance. Therefore, a volume of 0.7 mL was used as an optimum 
value. 
Reaction Mechanism 
DDQ is a acceptor, which reacts with n-donors to form coloured charge transfer 
complexes or radical anions depending on the polarity of the solvent used [16]. The roxatidine 
base acting as n-donor readily reacts with DDQ resulting in the formation of reddish violet 
chromogen, which showed absorption maxima at 440, 530 and 565 nm (Fig. 3.5). The bands 
may be due to the formation of DDQ radical anions arising from the complete transfer of n-
electrons from donor to acceptor moiety in acetonitrile. In order to avoid the maximum 
interference from the reagent blank, the absorption band peaking at 530 nm was selected for 
analytical studies. 
p-chloranilic acid in dioxane chloroform exists in unionised form and acts as k acceptor 
similar to quinones [17]. The absorption spectrum of p-chloranilic acid in dioxane-chloroform 
exhibits an absorption band at 440 nm. The addition of roxatidine base to p-chloranilic acid 
results in the formation of a charge transfer complex of the n-n type. This compound is 
believed to be an intermediate molecular association complex, which dissociates in the 
corresponding radical anion in dioxane-chloroform solvent. The p-chloranilic acid radical anion 
absorbs maximally at 530 nm (Fig. 3.5). The stoichiometry of the reactions was studied by 
Job's method of continuous variation [18]. It was found that the complexation ratio was 1:1 
108 
0.8 1 
0.6 
(U 0 
c 
TO 
1 0 .4 
(A 
XI < 
0.2 -
0.0 
0.0 0.3 0 .6 0 .9 
Volume of pCA (mL) 
1.2 
Fig 3.4 Effect of the volume of 0.2% p-chloranilic acid on 
the absorbance 
109 
400 450 500 
Wavelength (nm) 
Rg 3.5 Absorption spectra 
{ • ) RAH-DDQ complex 
(o) RAH-p-chloranilic acid complex 
110 
(acceptor: donor) for DDQ and p-chloranilic acid with roxatidine b^se (Fig. 3.6 and 3.7). This 
indicated the presence of one n-donating centre in the roxatidine base molecule. On the basis 
of literature background and our experimental results, the tentative reaction mechanisms for 
roxatidine-DDQ and roxatidine-p-chloranilic acid complexes have been proposed and given in 
scheme 3.1 and 3.2, respectively. 
The Benesi-Heldebrand equation [19] has been used to calculate the association 
constant and apparent molar absoptivity of the charge transfer complexes. This depends on 
the experimental conditions that one of the two component species should be present in large 
excess so that its concentration is virtually unchanged on formation of charge transfer complex. 
In the present study, the donor-acceptor systems were studied within a restricted 
concentration range. The acceptor concentrations were not low enough to be considered 
negligible with respect to donor concentration and therefore, Ross and Labe equation [20] was 
applied to calculate the association constant of the charge transfer complexes. 
[A][D] y ^ ^ X 1 4. - J _ 
[A] + [D] A, K8 , [A] + [D] 8, 
[A] and [D] refer to molar concentration of acceptor and donor, respectively. A^ is the 
absorbance at wavelength X. K and e^ are the association constant and molar absoptivity, 
respectively. The values of association constant were obtained from the plots of 
[A][D]/[A] + [D] X 1/ Ax vs. 1/[A] + [D] (Fig. 3.8 and 3.9) for both the charge-transfer 
complexes. 
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The association constants and free energy change, AG, for roxatidine-DDQ and 
roxatidine-p-chloranilic acid complexes were found to be 3.45x10^; 3.84x105 and -14.96; -
32.93 KJ mol-\ respectively. 
Analytical data 
Under the optimum experimental conditions the main figures of merit for both the 
procedures for determination of roxatidine acetate hydrochloride have been established by 
least square treatment of the results. The Beer's law limit, equation parameters, correlation 
coefficient, detection limit [21], variance and sandell's sensitivity for both the methods are 
summarized in Table 3.1. The small values of variance obtained for both the methods indicated 
negligible scattering of the experimental data points from the line of best fit. 
The high value of correlation coefficient and small value of the intercept on the 
ordinate, which was close to zero, validated the linearity of calibration curves whereas detection 
limit and slope indicated the good sensitivity of the methods. 
It is possible to evaluate the error, Sc, in the determination of a given concentration of 
RAH [22] by regression analysis of calibration data. Figs. 3.10 and 3.11 show the graph of Sc 
against the concentration of RAH. It is apparent from the figures that the minimum error is 
encountered when determination is done at a concentration level of 35 and 130 |ig mL^ for 
DDQ and p-chloranilic acid methods, respectively. This statistical treatment can be used to 
establish confidence limit, at the selected level of confidence, for determination of unknown 
concentration using the equation [21 ]; 
c , ± 
_ 2 -
" b ^ C I C ^ - n C ^ ) 
= C i ± A C 
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Where y and C are average absorbance and concentration values, respectively, for 
n standard specimen. The results are shown graphically in Fig. 3.12 and 3.13 in the form 
of percent uncertainty vs. the concentration at 95% confidence level and used to calculate the 
relative uncertainty in the concentration over the full range of concentration tested. It is 
therefore, a guide to establish the confidence limit. 
To test the precision and accuracy of the proposed methods, six successive 
determinations at three different concentration levels of roxatidine were performed. The results 
are summarized in Table 3.2, which shows that the methods are satisfactorily reproducible. The 
recovery experiments were performed by standard addition method. For this a fixed amount of 
roxatidine was added to a preanalysed tablet and determined by proposed methods. The 
results are shown in Table 3.3. It is apparent from the table that mean recoveries were in the 
range of 99.10% to 100.02%. No interferences from the common excipients were observed. 
The methods were successfully applied to the determination of roxatidine in two 
different formulations. The results of the proposed methods (DDQ or p-chloranilic acid) were 
compared with those of the developed UV reference method. Table 3.4 shows that the 
calculated t- and F- values are less than the theoretical ones, confirming accuracy and 
precision at 95% confidence level. 
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Introduction 
Lansoprazole (L), 2-({3-Methyl-4-(2,2,2-trifluroethoxy)-2-pyridyl) methyl} sulphinyl 
benzimidazole, is a new substituted bezlnfiidazole compound that effectively decreases gastric acid 
secretion via inhibition of gastric H"^ , K+-adenosine triphosphatase [1]. Like omeprazole, 
lansoprazole is thought to be a weak inducer of hepatic cytochrome P450. It is an important 
alternative to omeprazole and Ha receptor antagonists in acid related disorders. In addition to its 
efficacy in healing or maintenance treatment, it may provide more effective symptom relief than 
other comparator agents [2]. The drug is acid labile and administered in the form of enteric-
coated granules in capsules. 
Control of the contents of commercially available medication is stringent and 
pharmaceutical companies have been using analytical methods to determine the purity of their 
products. Several methods have been reported for the determination of lansoprazole in biological 
fluids and pharmaceutical dosage forms. These methods are HPLC [3 - 7], HPTLC [ 8 - 9 ] , 
capillary electrophoresis [10] and electroanalytical methods [11 -12 ] . 
Few spectrophotometric methods have also been presented for quantification of the cited 
drug. It was determined by reacting with p-dimethylaminobezaldehyde in acidic medium [13], 
Meyyanathan et ^/have reported [14] two spectrophotometric methods. One method was based 
on the reaction of lansoprazole with acetyl chloride In the presence of 1% CUSO4 solution. The 
resulting yellowish red chromogen exhibited absorption peak at 478.5 nm, Beer's law was obeyed 
in the concentration range 100 - 600 pg mL"'. In the second method lansoprazole was treated 
with methylbenzothiazolinone hydrazone in presence of Ce(IV) resulting in the formation of a coloured 
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chromogen, which absorbed maximally at 491 nm. The folin docalteu reagent [15] has also been 
used for determination of cited drug in the concentration range 0.5 - 5.0 pg ml"' at 654 nm. The 
ion pair complex [16] formed between lansoprazole and bromocresol green can be extracted with 
organic solvent, which absorb maximally at 420 nm. The assay was carried out in the concentration 
range 1 - 2 0 |jg m l ' l The quantification of lansoprazole was made possible by reacting it with 
vanillin in acidic medium [17]. 
Kinetic methods have been used for assay of drugs in pharmaceutical formulations as some 
specific advantages are involved, namely: (i) Selectivity due to measurement of the evolution of the 
absorbance with time of reaction instead of measure of a concrete absorbance value, 
(ii) Possibility of no interference of the coloured and/or turbidity background of the sample. In the 
literature, no kinetic spectrophotometric method has been reported yet for determination of 
lansoprazole. Therefore, there is a need to develop a simple and fast kinetic method. 
The present work describes two spectrophotometric methods for the determination of 
lansoprazole in pharmaceutical formulations based on the formation of complexes with Fe(lll) and 
Zn(ll). The methods were validated statistically. 
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Experimental 
Apparatus 
All spectral and absorbance measurements were made on spectronic 200"^  
spectrophotometer (Milton Roy, USA), with 1cm matched glass cells. 
Materials and reagents 
Lansoprazole was kindly provided by Cipla Ltd., India, and was used as received. Four 
different pharmaceutical preparations such as Lancus (Cadila Pharma), Lansofast (Zydus Alidac), 
Lanzol (Cipla Ltd.) and Propilan (Glenmark) were purchased from local market. All other reagents 
used were of analytical reagent grade. 
Standard solutions 
(i) Ferric chloride solution, 4.93 x 10'^ M, was prepared in ethanol. 
(ii) Zinc chloride solution, 8.0 x lO-^M, was prepared in ethanol. 
(iii) Standard solution of lansoprazole (3 mg mL"^ ) was prepared in ethanol and further 
diluted according to need. 
Lansoprazole solution was freshly prepared and used within 5 hours. 
Recommended procedures 
MethodA 
Accurately measured aliquots (0.5 mg - 2 mg) from standard solution of lansoprazole 
were transferred into a 10 mL volumetric flask followed by 0.8 mL of FeCb solution, and diluted to 
the volume with ethanol. The mixture was shaken well and transferred to the spectrophotometric 
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cell (within 1 minute) and evolution of the absorbance was measured at 445 nm with time for 35 
minutes. 
The initial rate of the reaction was calculated as tangent to the kinetic curve at different 
concentrations. The calibration graphs were constructed by plotting (i) the logarithm of the initial 
rate of the reaction vs. the logarithm of the molar concentration of lansoprazole and (ii) the 
absorbance measured at a fixed time of 5 min. against the concentration of lansoprazole (Fig. 4.1 
and 4.2). Its content was estimated either from the calibration curves or corresponding calibration 
equations. 
MethodB 
Into a series of 10 mL volumetric flasks, volumes equivalent to 1.2 - 3.0 mg of 
lansoprazole were pipetted, 1.8 mL of ZnCIa solution was added to each flask and the volume of 
the flask was brought up to the mark with ethanol. The evolution of absorbance was recorded as a 
function of time at 510 nm against the reagent blank prepared simultaneously at room 
temperature. 
The initial rate of reaction at different concentrations was obtained from slope of the 
absorbance time curve. The calibration curves were obtained by plotting (i) logarithm of the initial 
rate of the reaction vs logarithm of the molar concentration of lansoprazole and (ii) the 
absorbance measured at a fixed time of 15 min. against the lansoprazole concentration (Fig. 4.3 
and 4.4). The content of the drug was computed either from the calibration curves or regression 
equations. 
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Fig. 4.1 Calibration curve for the determination of lansoprazole using method A 
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Fig. 4.2 Calibration curve for determination of lansoprazole using method A 
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Fig. 4.4 Calibration curve for determination of lansoprazole using method B 
at a fixed time of 15 min. 
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Analysis of capsules 
The content of the capsules (enteric coated granules) were accurately weighed and finely 
powdered. The amount of the powder equivalent to 150 mg of lansoprazole was dissolved in 40 
mL of ethanol and allowed to stand for few minutes and filtered on Whatman No. 42 filter paper. 
The residue was completely washed with ethanol. The filtrate was diluted to 50 mL with ethanol. 
This solution is further diluted according'to need. The assay of lansoprazole was completed by 
following the recommended procedures. 
Results and discussion 
The organic compounds have long been utilized as analytical reagent for the determination 
of metal ions via formation of metal complexes. However, the binary complexes of lansoprazole with 
metal ions have not been studied yet, although they may be of biological significance. These may 
affect the bioavailibility of the cited drug, as certain metal ions are present in relatively appreciable 
concentrations in biological fluids. At room temperature, the chelation reaction of lansoprazole with 
Fe(lll) and Zn(ll) were slow and the intensity of the colour increases with time. Therefore, kinetically 
based methods were elaborated for quantification of the drug. The various experimental 
parameters affecting the metal chelate formation were optimised. 
The equilibrium for the chelation reaction between lansoprazole and Fe(lll) is reached in 
about 35 minutes. To study the effect of the concentration of Fe(lll), aliquots containing 2.0 mg of 
the drug were pipetted into a series of 10 mL standard flasks followed by varying volumes (0.1 -
1.0 mL) of 4.93 x lO'^ M reagent and diluted to volume with ethanol. The absorbance was 
measured after 35 min. of mixing. The maximum absorbance was obtained with 0.6 mL of the 
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reagent. Higher volume of Fe(lll) yielded no change in absorbance (Fig. 4.5) and hence, 0.8 mL 
was chosen as optimum value for all measurements. 
To establish the optimum experimental conditions for method B, the cited drug (300 pg 
mL"^ ) was allowed to react with varying volumes (0.2 - 2.0 mL) of 0.08M zinc chloride solution. 
The absorbance at 510 nm was measured at a fixed time of 25 minutes. It is apparent from the 
Fig. 4.6 that the absorbance increased "With increasing volume of InQz solution and became 
constant at 1.5 mL; further addition caused no change in absorbance. Therefore 1.8 mL was 
adopted in the final solution proving to be adequate for maximum concentration of lansoprazole 
used in kinetic determination. 
Reaction Stoidiiometry 
The combining ratio between metal ion and lansoprazole was established by the Job's 
method of continuous variation [18], mole ratio method [19] and limiting logarithmic method 
[20]. Figures 4.7, 4.8 and 4.9, 4.10 indicated the formation of 1:1 lansoprazole:Fe(lll) and 2:1 
lansoprazole:Zn(ll) complexes. The beads of the strong cation exchange resin in Na+ form were 
placed in the ethanolic solution of the complex to ascertain the ionic nature. The results suggested 
positive charge on lansoprazole-Fe(lll) complex and no charge on lansoprazole-Zn(ll) complex. 
Based on the literature background and our experimental findings, the reaction mechanisms are 
proposed and given in schemes 4.1 and 4.2. 
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Kinetic study of the reaction 
The initial rates of tiie reactions were determined by measuring tfie slope of the initial straight 
line of the absorbance-time curves. The rate of the reaction was found to be dependent upon the 
concentration of lansoprazole. The rates were followed at room temperatures: 
(a) with various concentrations of lansoprazole in the concentration range of 0.05 - 0.2 mg 
mL-\ keeping Fe(lll) concentration constant and high (method A) 
(b) keeping a constant and high concentration of Zn(ll) and varying the lansoprazole 
concentration in the range of 0.12 - 0.3 mg mb^ (method B) 
Figure 4.11 and 4.12 obtained by applying methods A and B revealed the fact that the rate 
increases with increasing lansoprazole concentration. The reaction rates obey the following 
equation: 
rate = AA/At = K' [lansoprazole]" 
where A"is the pseudo-order constant of the reaction and n is the order of the reaction. The above 
equation is transformed into logarithmic equation as: 
log (rate) = log A"+ n log [lansoprazole] 
Regression of log rate versus log [lansoprazole] gave the regression equation: 
(1) For method A, 
log (rate) = 2.861 + 1.191 x log [lansoprazole] 
(y = 0.9977) 
1^9 
1.0 -
Fig. 4.11 Absorbance vs. time graph for the reaction between lansoprazoie and 
Fe(lll), showing the dependence of the reaction on lansoprazole concentration 
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Fig. 4.12 Absorbance vs. time graph for the reaction between lansoprazole and 
Zn(ll), showing the dependence of the reaction on lansoprazole concentration 
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(2) For method B, 
log (rate) = 4.723 + 2.007 x log [lansoprazole] 
(Y = 0 . 9 9 7 2 ) 
The regression equation also indicated that the reaction is first order with respect to the 
lansoprazole concentration for method A and a second order reaction kinetics with respect to the 
drug concentration for method B. 
Under the optimum experimental conditions the quantification of the cited drug was carried out 
using an excess of Fe(lll) and Zn(ll) with respect to initial concentration of lansoprazole by 
methods A and B, respectively. Therefore pseudo-zero order condition is obtained with respect to 
Fe(lll) and Zn(ll) concentrations. However, the rates will be related to lansoprazole concentration 
in a pseudo-order condition as follows: 
rate = K' [lansoprazole] method A 
rate = K' [lansoprazole] ^  method B 
The regression analysis indicated linear relationship between log rate and log molar 
concentration of drug. The calibration curves were found to be linear over the concentration ranges 
50 - 200 [jg mL-' and 120 - 300 pg mL' for methods A and B, respectively. The high value of 
correlation coefficient pointed toward good linearity of both the calibration curves. The confidence 
intervals [21] for intercept and slope were calculated using relations ± /Sa and ± /Sband found 
to be 3.395 x 10-2 ; 4.568 x 10-^  and 5.663 x 10-^; 1.310 x 10-' for methods A and B, 
respectively which showed high reproducibility of the proposed methods. The detection limits [22] 
were calculated using the equation 
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Detection limit = [ So^  (n-2) /(n-1)]'/2 (t/b) 
where n is the number of samples; b is the slope of line of regression; t- is the students /-value at 
95% confidence level and So^  is the variance. 
The detection limits were found to be 0.03 and 0.02 pg mL'^  for methods A and B, 
respectively. The low value of variance (3.299 x 10 '' and 6.542 x 10"'' for methods A and B) 
obtained in each method indicated the negligible scattering of data points around the line of best 
fit. 
Fixed-time method 
At a preselected time, absorbance was measured. The calibration curve of absorbance versus 
initial concentration of lansoprazole is obtained for each method at a fixed time of 5, 15 and 25 
min. The linear concentration range, molar absorptivity, regression equation, correlation coefficient 
and variance are given in Table 4.1. It is evident from the Table 4.1 that the slope increases with 
time and the most acceptable values of correlation coefficient and intercept are obtained at a fixed 
time of 5 min and 15 min for methods A and B, respectively and therefore, selected as most 
suitable time intervals for determination. 
Precision 
Repeatability 
Repeatability was determined by assaying six samples of 120 and 80 mL ' using 
lansoprazole-Fe(lll) system for initial-rate and fixed time methods, respectively. For lansoprazole-
Zn(ll) system, six replicate determinations of 150 and 210 |j,g mL"' were performed utilizing initial-
rate and fixed time methods, respectively. The results are summarized in Table 4.2 
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Lansoprazole recoveries ranged from 99.78 to 99.73% with a mean of 0.91% and 0.82% 
RSD for lansoprazole-Fe(lll) system using initial rate and fixed time methods. For initial-rate and 
fixed time methods of lansoprazole-Zn(ll) system, the recoveries ranged from 100.10 to 100.13% 
with a mean of 0.62% and 0.32% RSD. 
Reproducibility was evaluated by determining four different lansoprazole concentrations in 
triplicate over a period of six days. Results of inter-day reproducibility are given in Table 4.3. The 
inter-day and intra-day precision data showed good accuracy and precision of the proposed 
procedures for analysis of lansoprazole. 
As an additional demonstration of accuracy, recovery experiments were carried out by 
standard addition technique. In this method, a fixed amount of pure lansoprazole was added to 
preanalysed commercial dosage forms and content was determined by the proposed procedures. 
The results are summarised in Table 4.4 and 4.5. It is apparent fiom the tables that common 
excipients present in dosage forms did not interfere with the determination. 
The proposed methods have been successfully applied to the determination of lansoprazole in 
some commercial preparations. The results obtained by proposed procedures were compared to 
those of reference method [14]. The student's t- and F- values at 95% confidence level did not 
exceed the theoretical values, (Table 4.6 and 4.7) indicating no significant difference between 
accuracy and precision of the two methods. 
The interval hypothesis [23] was also applied to judge the reliability of the proposed 
procedures. For this it is decided that a bias expressed as a proportion of the reference mean of 
± 2 % is acceptable. Therefore, the acceptable interval is [ G L = 0 . 9 8 and 9 U = 1 . 0 2 ] , At 9 5 % 
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confidence level the different set of results are summarised in Table 4.8. It is concluded based on 
these intervals that the proposed procedures are not biased, as true bias is smaller than ±2%. 
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Introduction 
Pantoprazole, B-difluromethoxybenzimidazole-Z-yl 3,4-dimethoxy-2-pyridylmethyl 
sulphoxide, is an irreversible proton pump inhibitor which has been developed for the treatment of 
acid-related gastrointestinal disorders. The drug is listed in Martindale - The Extra Pharmacopoeia 
1]. Pantoprazole reduces gastric acid secretion through inhibition of the proton pump on the 
gastric parietal cell. It is a week base (pKa= 3.9), which ionises at low pH and readily accumulates 
in the highly acidic canalicular lumen of the stimulated parietal cell [2]. In this acidic environment 
pantoprazole is rapidly converted to a cationic cyclic sulphonamide which binds covalently to 
cysteine residues on the luminal surface of H+, K+-ATPase to form a mixed disulphide, thereby 
causing irreversible inhibition of gastric proton pump function. The drug has lower affinity than 
omeprazole or lansoprazole for hepatic cytochrome P450 and shows no clinically relevant 
pharmacokinetic or pharmacodynamic interactions with diazepam [3], carbamazepine [4], 
phenytoin [5] and warfarin [6]. Owing to the pharmacological importance, analytical methods for 
routine quality control of pantoprazole in dosage forms are required. 
Literature survey reveals few HPLC [7 - 9] methods for the determination of cited drug in 
biological fluids and tablet formulations. Chiral resolution of pantoprazole and related sulphoxide by 
capillary zone electrophoresis [10] has been reported. A voltammetric method [11] was 
described for the determination of pantoprazole by differential pulse adsorptive stripping 
voltammetry at a carbon paste electrode. Under optimised conditions, the current showed a linear 
dependence with concentration in the range 1.0x10"^ - 1.0x10-^M and the detection limit was 
2.0x10"®M. Recently spectrophotometric procedures for the determination of pantoprazole have 
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been developed: two methods based on charge transfer complexation with 2,3-dichloro 5,6-
dicyano 1,4-benzoquinone and iodine and third method depending on ternary complex formation 
with eosin and copper(ll) [12]. The cited drug is quantified by a stability indicating procedure 
through chelation with Fe(lll) in aqueous-ethanol medium to form an orange chelate which 
absorbed maximally at 455 nm [13]. Beer's law was obeyed in the concentration range of 30 -
300 |ag ml-\ The first-order UV-derivative spectrophotometry using zero-crossing method [14] 
was developed for the determination of pantoprazole in methanol-ammonia (4.0 v/v) where 
sufficient spectra resolutions of drug and its impurity were obtained. Wahbi et at. have reported 
[15] the compensation method and other chemometric methods such as derivative, orthogonal 
function and difference spectrophotometry for direct determination of the cited drug in dosage 
forms. 
This chapter describes a stability-indicating kinetic spectrophotornetric method based on 
the reaction of the pantoprazole with 1-fluoro-2,4-dinitrobenzene (FDNB) in dimethylsulphoxide 
(DMSO) medium. 
Experimental 
Apparatus 
Spectral runs and absorbances were recorded on Spectronic 20 D+ spectrophotometer 
(Milton Roy, USA) with matched glass cuvettes. 
Materid and reagents 
Pantoprazole sodium sesquihydrate was kindly provided by Concept Pharmaceuticals, India 
Ltd. Its purity was checked by TLC and melting point [16 . 
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Commercial preparations of pantoprazole were purchased from local market. All other 
reagents used were of analytical reagent grade. 
Standard so/utions 
(i) FDNB solution, 0.2% v/v, was prepared in DMSO. It was protected from light and 
stored in refrigerator. 
(ii) Standard pantoprazole solution (0.25 mg mL') was prepared in DMSO. 
Laboratory-degraded pantoprazole 
100 mg of pantoprazole was dissolved in 200 mL of borate buffer (pH 8) and kept at 
room temperature {= 30 °C) for 7 days. Reddish brown precipitate of sulfinamide degradate 
was filtered and the filtrate was evaporated to dryness under vacuum. The residue was 
extracted three times with 20 mL ethanol. The combined ethanolic extracts were evaporated to 
dryness under vacuum and the residue was dissolved in distilled water and diluted to 50 mL. 
The resulting solution was labeled to contain the sulfenic acid degradate obtained from 2 mg 
mL"' of pantoprazole. This degradate solution was examined by TLC using silica gel and a 
mobile phase of chloroform-methanol (10:0.4) which confirmed that there was no undegraded 
pantoprazole. 
General procedure 
Aliquot from DMSO stock pantoprazole solution (0.25 mg mL-') corresponding to 50 -
100 |ug was pipetted into a 5 mL volumetric flask, followed by 1 mL of 0.2% FDNB solution 
and diluted to volume with DMSO. The mixture was shaken well and immediately transferred to 
spectrophotometric cell. The absorbance was measured at 420 nm as a function of time 
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against the reagent blank. The initial rates of the reaction at different concentrations were 
obtained from the slope of the initial tangent to the absorbance-time curves. 
The calibration curve was constructed by plotting logarithm of initial rate of reaction 1/5. 
logarithm of molar concentration of pantoprazole. The amount of the drug was computed 
either from the calibration curve or regression equation. 
Determinatm of mixtures of intad and degraded pantoprazole 
Aliquots of laboratory-degraded solution corresponding to 0.2 - 2.0 mg degraded 
pantoprazole were transferred into a series of 5 mL volumetric flasks. To each flask, 0.2 mL of 
pure pantoprazole (0.25 mg mL') prepared in DMSO was added and mixed well. The amount 
of pantoprazole was determined by the proposed method. 
Procedure for the determination of pantoprazole in commercial dosage forms 
Ten tablets were accurately weighed and finely powdered. The amount of the powder 
equivalent to 50 mg pantoprazole was dissolved in about 40 mL DMSO. Filtration was carried 
out through Whatman filter paper No. 42 and the filtrate was diluted to 100 mL with DMSO. It 
was further diluted according to the need. The assay was completed by following the 
recommended procedure. 
Results and discussion 
A coloured product was obtained when FDNB was added to pantoprazole in DMSO 
medium, which absorbed maximally at 420 nm (Fig. 5.1). At room temperature, the reaction 
was slow and more than one hour were required to attain the maximum absorbance. 
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Fig 5.1 Absorption spectra of (•) reagent blank against dimethylsulphoxide 
(o) sample against reagent blank 
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Therefore, a kinetically based method was developed to quantify the pantoprazole. The method 
has been extended to the determination of intact drug in presence of its degradation product. 
Pantoprazole was degraded completely in borate buffer of pH 8 at room temperature after 
seven days to yield two degradation products; sulfinamide and sulfenic acid derivative. The 
sulfinamide is insoluble in aqueous media and is separated by filtration for soluble sulfenic acid 
derivative. These degradation products were tested by TLC using silica gel-6 plate and 
chloroform-methanol (10:0.4) as mobile phase. The spots were detected under UV lamp at 
366 nm. Each degradate gave a single spot at Rf values of 0.75 and 0.26 for sulfinamide and 
sulfenic acid derivative, respectively. However, the Rf value of the intact drug was 0.54. 
To study the effect of the concentration of FDNB on initial rate of reaction, varying volume 
of 0.2% reagent was mixed with a fixed amount of pantoprazole (16 ^g mL') in a 5 mL 
volumetric flask. The absorbance of each solution was measured at a fixed time of 35 min. The 
absorbance increased with increasing volume and became constant at 0.8 mL; above this 
volume the absorbance remained unchanged (Fig. 5.2). Therefore, 1.0 mL was used 
throughout the experiment. 
The stoichiometry of FDNB to pantoprazole was established by limiting logarithmic method 
[17]. For this two sets of experiments were performed. In the first set, the concentration of the 
cited drug was varied while keeping a constant concentration of the FDNB. In the second set, 
the concentration of the cited drug was kept constant while varying the concentration of FDNB. 
The combining ratio was calculated from the slopes of the plots of logarithm of absorbance ys. 
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Fig 5.2 Effect of the volume of 0.2% FDNB on the intensity of colour 
produced during the reaction 
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logarithm of the respective concentration varied, (Fig. 5.3) and found to be 1:1 between 
pantoprazole and FDNB. 
The review of literature indicated that interesting colours are produced on addition of base 
to a polynitro aromatic which have been attributed to a variety of interactions [18 - 20]. In 
this study, pantoprazole acts as a base when it is added to FDNB. A proton transfer from FDNB 
to base is apparently responsible for colour formation. The early study has shown that DMSO 
stabilises the conjugation base of FDNB derivative and hence, a Meisenheimer complex is 
proposed for this colour formation. (Scheme 5.1). 
The rate of reaction was found to be dependent on pantoprazole concentration. The rates 
were followed at room temperature with different concentrations of the cited drug (Fig. 5.4). 
The initial rates of the reaction were obtained from the slope of the initial tangents to the 
absorbance-time curves, which indicated that the initial rate increases with increasing 
pantoprazole concentration. 
The order of the reaction with respect to the pantoprazole concentration was evaluated 
from the plot of logarithm of initial rate k?. logarithm of molar concentration of pantoprazole 
and found to be one. 
Under the established experimental conditions, the quantitative determination of 
pantoprazole in the presence of a large excess of FDNB concentration would result in a 
pseudo-zero order condition with respect to the reagent concentration. However, the initial 
rate would follow a pseudo first order reaction and obey the equation, 
rate= AA/At = k' C" 
195 
-0.2 
-0.4 
8 c (0 
€ 
J3 
<0 -0.6 O) o 
-0.8 
-5 -4 -3 
log molar concentration 
- 2 
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Fig 5.4 Absorbance ys. time graph for the reaction between pantoprazole 
and FDNB, showing the dependence of the reaction on pantoprazole 
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where k ' is the pseudo-order rate constant, C is the concentration of pantoprazole , n is 
the order of reaction. 
The above equation can be written in logarithmic form as: 
log (rate) = log X-' + n log C 
The regression analysis using the method of least square was performed to estimate the 
slope, intercept and correlation coefficient. Under the established experimental conditions, a 
calibration graph (Fig. 5.5) was constructed by plotting log initial rate vs. log molar 
concentration of pantoprazole showing a linear response over the concentration range of 10 -
20 |xg mL-i. 
The regression analysis yielded the following regression equation, 
log (rate) = 3.570 + 1.222 logC 
with a correlation coefficient of 0.9979. 
The confidence limit for the intercept value at 95% confidence level was calculated using 
the relation a±/ S^and was found to be 3.570±2.37x10-2 which pointed towards a high 
reproducibility of the method. The limit of detection [21] and variance were evaluated and 
found to be 1.65x10-2 ^g mL'^ and 1.113x10•^ respectively. The small value of variance 
confirmed the negligible scattering of the calibration data point around the line of the 
regression. 
The selectivity of the proposed method for pantoprazole was checked by direct 
determination of the intact drug in presence of its degradate, sulfenic acid, in different 
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amounts. The percent recovery (Table 5.1) is quite satisfactory and thus the proposed method 
can be used for stability indication. 
The accuracy and precision of the proposed method was evaluated by determining the 
pantoprazoie content of pure sample six times within one day (Table 5.2). The inter day 
precision was measured by assaying the pure sample on five consecutive days and results are 
summarised in Table 5.3. The Standard deviation, relative standard deviation and standard 
analytical errors encountered in intraday and Interday assays can be considered to be very 
satisfactory. 
The developed method was successfully applied to the assay of pantoprazoie in tablets; 
the results are given in Table 5.4. The same batch tablets were also analysed by the reference 
method [12]. The results of the proposed method were compared with those of reference 
method using point hypothesis. It is apparent form Table 5.4 that the calculated t- and F-
values are less than the theoretical ones at 95% confidence level, which showed no significant 
difference with regard to accuracy and precision. The reliability and accuracy of the proposed 
method was further confirmed by recovery study through standard addition method. A known 
amount of the pure drug was added to the preanalysed tablets at three different levels and the 
total amount was determined by the proposed method. Each level was repeated six times using 
four different market formulations. The percent recoveries and RSD (Table 5.5) indicated that 
the commonly encountered tablet excipients did not interfere with the determination. 
The interval hypothesis tests have also been carried out for comparison of the results 
obtained by proposed and reference methods at 95% confidence level (Table 5.6). For 
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Table 5.1 Determination of pantoprazole in laboratory prepared mixtures with its degradate, 
sulfenic acid derivative, by the proposed method 
10 80 10.002 100.02 
10 120 10.00 100.00 
10 160 9.98 99.82 
10 280 9.95 99.51 
10 320 10.01 100.10 
10 400 10.02 100.25 
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Table 5.2 Intra day assay: evaluation of accuracy and precision of the proposed method 
Amount (yig mL'^ ) 
Taken Found ±SD Recovery ±RSD SAB 
(%) 
12 
16 
20 
11.86±0.10 
16.04+0.08 
19.90±0.12 
98.8410.85 
100.25+0.52 
99.52±0.60 
0.041 
0.034 
0.049 
® Standard analytical error 
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Amount (^ig mL'^ ) 
Taken Found ± SD Recovery ±RSD 
(%) 
SAB 
12 11.88±0.07 99.01 ±0.61 0.029 
16 15.86±0.09 99.14±0.60 0.038 
20 19.80±0.14 98.98+0.71 0.057 
' Standard analytical error 
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Table 5.5 Standard addition method for the determination of pantoprazole in dosage forms 
Formulation Amount (fig mL*^ ) Recovery ± RSD 
(%) 
SAP 
Taken Added FoundtSD 
PAN-40 5 5 9.89±0.15 98.85±1.56 0.063 
6 10 16.01 ±0.08 100.0+0.50 0.033 
12 6 17.99±0.15 99.99+0.83 0.061 
Pantodac 5 5 9.97±0.08 99.71 ±0.87 0.035 
6 10 16.00±0.16 100.01±1.06 0.069 
12 6 17.98±0.11 99.92±0.62 0.045 
Pantop 5 5 9.98±0.07 99.87±0.74 0.030 
6 10 15.96±0.11 99.77±0.69 0.45 
12 6 18.02±0.12 100.13±0.69 0.050 
Pantocid 5 5 9.97±0.12 99.69±1.28 0.052 
6 10 15.98+0.10 99.93±0.66 0.043 
12 6 18.04±0.13 100.27±0.75 0.055 
'Standard analytical error 
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Table 5.6 Interval hypothesis: comparison of the results of the proposed method with a reference 
method 
Formulation Gl 9i u 
PAN-40 0.990 1.004 
Pantodac 0.994 1.009 
Pantop 0.988 1.003 
Pantocid 0.982 1.011 
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pharmaceutical analysis, a bias of ±2% is acceptable and thus the limit of acceptance interval 
is within 9 l= 0.98 and 9u= 1.02. Table 5.6 shows that the true bias of all samples is smaller 
than ±2%. 
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Kinetic Spectrophotometric Determination of Famotidine in 
Commercial Dosage Forms 
Nafisur RAHMAN^ and Mohammad KASHIF 
Analytical Research Division, Department of Chemistry, Aligarh Muslim University, 
Aligarh (U.P.) 202002, India 
A simple kinetic spectrophotometric method is described for the determination of famotidine. The method is based on the 
oxidation of the drug with alkaline potassium permanganate. The reaction is followed spectrometrically by measuring the 
rate of change of the absorbance at 610 nm. The initial-rate and fixed-time (at 12 min) methods are adopted for 
determining the drug concentration. The calibration graphs are linear in the ranges of 2 - 10 ng mL"' and 1 - 8 ng mL"' 
using the initial-rate and fixed-time methods, respectively. The method has been applied to the determination of 
famotidine in tablet formulations. The obtained results are compared statistically with those given by a reference 
spectrophotometric method. 
(Received March 10,2003; Accepted March 25,2003) 
Introduction 
Famotidine, 3-[2-(diaminomethyleneamino)thiazol-4-
ylmethylthio]-A^-sulfamoylpropionamidine, is a histamine Hi 
receptor antagonist, with actions and uses similar to those of 
cimetidine. It is widely used in the management of gastro-
intestinal disorders, such as aspiration syndrome, dyspepsia, 
gastro-esophageal reflux disease, peptic ulcer and Zollinger-
Ellison syndrome.' 
This drug is listed in United States pharmacopoeia,^ which 
recommends non-aqueous titration and HPLC methods for its 
assay in bulk and tablet formulations, respectively. 
UV-visible spectrophotometry is still considered to be a very 
convenient and low-cost technique, and hence is widely used for 
the determination of pharmaceuticals in bulk and dosage forms. 
A review of the literature revealed that charge-transfer 
complexation reactions between famotidine and k acceptors, 
such as 1,4-benzoquinone,' chloranil, dichlorodicyano-
benzoquinone, dichloronitrophenol^ and p-chloranilic acid,' 
have been recommended for its determination in commercial 
tablet formulations. Extractive spectrophotometric methods' 
have also been discussed which involve dichloromethane 
extractable 1:1 ion pair complex between famotidine and each 
of Bromocresol Green (BCG) and Bromothymol Blue (BTB). 
Beer's law was obeyed over the concentration ranges of 2.0 -
23.6 and 0.7 - 8.1 Hg mL"' with molar absorptivities of 5.0 x 10' 
and 1.2 x 10* L moh' cm"' for famotidine-BCG and famotidine-
BTB, respectively. The famotidine content was determined 
based on a reaction with sodium nitroprusside and measuring 
the absorbance at 498 nm.' The difference spectrophotometric 
and quadratic polynomial coefficient methods' have been cited 
in the literature for the determination of famotidine in 
pharmaceutical preparations. 
A number of other techniques, such as HPLC,'^''' reversed-
' To whom correspondence should be addressed. 
E-mail: chtl7nr@yahoo.co.in 
phase HPLC," HPTLC" and differential pulse voltammetry," 
and potentiometric titration," have been reported for the assay 
of famotidine in commercial dosage forms. Several 
manipulation steps are involved in some of these methods, 
which are not simple for the routine analysis of dosage forms. 
The present communication describes a kinetically based 
spectrophotometric method for the determination of famotidine 
in pharmaceutical formulations. The method involves oxidation 
of the drug with alkaline potassium permanganate at room 
temperature and a subsequent measurement of the absorbance at 
610 nm. The initial-rate and fixed-time methods are adopted 
after a full investigation. 
Experimental 
Apparatus 
Spectronic 20 D* Spectrophotometer (Milton Roy, USA) was 
used to measure the absorbance. 
Materials and reagents 
Famotidine was kindly provided by Wockhardt Ltd., India, 
and was used as received. Pharmaceutical preparations of 
famotidine, such as Topcid (Torrent Pharmaceuticals Ltd.), 
Famocid (Sun Pharmaceutical Industries Ltd.), Famotin (USV 
Ltd.) and Facid (Intas Labs Pvt. Ltd.), were purchased from 
local market. All other reagents used were of analytical grade. 
A standard solution of famotidine (1 mg mL*') was prepared 
by dissolving 100 mg in 0.5 mL of 1 M NaOH, and further 
diluted to 100 mL with doubly distilled water. A working 
solution of famotidine (0.1 mg mL"') was prepaied-by the 
dilution of 2.5 mL of the standard solution to 25 mL with 
doubly distilled water. Aqueous solutions of sodium hydroxide 
(1 M) and potassium permanganate (0.01 M) were prepared in 
doubly distilled water. 
Procedure for determination 
Initial-rate method. Aliquots of 0.01 M KMn04 solution (1.0 
908 ANALYTICAL SCIENCES JUNE 2003, VOL. 19 
V o l u n w o f K M n O ^ l m L ) 
Fig. 1 Effect of the volume of 0.01 M KMnO^ on the intensity of 
the color produced during the reaction (famotidine 10 ng mL*'; 1.5 
m L o f l M N a O H ) . 
0 6 
8 
I 04 g 
5 
0.2 
09 15 
V o l u m e Of N a O H ( m L ) 
Fig. 2 Effect of the volume of 1 M NaOH on the intensity of color 
produced during the reaction (famotidine 10 ng mL''; 1.0 mL of 0.01 
M KMnOi). 
mL) and 1 M NaOH solution (L5 mL) were transferred into a 
10 mL volumetric flask. An accurate volume of the working 
solution of famotidine (0.2 - 1.0 mL) was added and diluted to 
volume with doubly distilled water. The contents of the mixture 
were shaken well and immediately transferred to a 
spectrophotometric cell. The absorbance was recorded as a 
function of time at 610 nm against a reagent blank at room 
temperature. The initial rate of the reaction at different 
concentrations was obtained from the slope of the tangent to the 
absorbance time curve. 
A calibration graph was constructed by plotting the logarithm 
of the initial rate of the reaction vi. the logarithm of the molar 
concentration of famotidine. In the second procedure, the 
absorbance measured at a fixed time of 12 min was plotted 
against the final concentration of famotidine. The content of the 
drug was calculated either ftom the calibration graphs or 
regression equations. 
Procedure for the determination of famotidine in 
pharmaceutical formulations. Ten tablets were accurately 
weighed and powdered. A portion equivalent to 50 mg of 
famotidine was extracted with methanol by shaking and filtered 
on Whatman No. 42 filter paper. The filtrate and washings 
were evaporated to dryness. The residue was dissolved in a 
minimum volume of 1 M NaOH and diluted according to need. 
The assay of famotidine was completed by the following 
recommended procedures. 
Results and Discussion 
In an alkaline medium, potassium permanganate oxidizes 
famotidine, resulting in the formation of manganate ion, which 
showed an absorption peak at 610 nm. Because the intensity of 
the color increased with time, a kinetically based method was 
elaborated for the determination of famotidine in dosage forms. 
The various experimental parameters affecting the formation of 
the reaction product were optimized. 
Effect of the KMnO^ concentration 
To study the effect of the KMnOi concentration, aliquots of 
famotidine containing 1(X) ^g mL"' were transferred into a 
series of 10 mL volumetric flasks, followed by varying volumes 
of 0.01 M KMn04 (0.1 - 1.0 mL) and 1.5 mL of 1 M NaOH 
solutions. The absorbance at 610 nm was measured at a fixed 
time of 16 min. It is apparent from Fig. 1 that the absorbance 
increased with increasing volume of the KMn04 solution, and 
became constant at 0.8 mL. Thus, the adoption of 1.0 ml of 
( o g M o l K C o n c m l n t i o n 
Fig. 3 Determination of the molar ratio between famotidine and 
KMn04 by the limiting logarithmic method. ( • ) Constant KMn04 
concentration and variable famotidine concentration, ( o ) Constant 
famotidine concentration and variable KMn04 concentration. 
0.01 M KMn04 in the final solution proved to be adequate for 
the maximum concentration of famotidine used in the 
calibration curve. 
Effect of the NaOH concentration 
The influence of the NaOH concentration on the formation of 
Mn04^" was examined critically. It was observed (Fig. 2) that 
the maximum absorbance of the reactant solution was obtained 
with 1.2 mL of 1 M NaOH. Hence, an optimum value of 1.5 
mL was used throughout the experiment. 
Stoichiometry 
The combining ratio between potassium permanganate and 
famotidine was established by limiting the logarithmic method" 
using two sets of experiments. In the first set, the famotidine 
concentration was varied while keeping a constant KMn04 
concentration; in the second set, the KMn04 concentration was 
varied while keeping a constant concentration of famotidine. 
The logarithms of the absorbance were plotted against the 
logarithms of the varied concentration (Fig. 3). The combining 
molar ratio was obtained from the slope of the curves, and was 
found to be 1:1 famotidine/KMn04. 
The famotidine contains a thio ether linkage which has an 
ability to oxidize to the corresponding sulfoxide. Based on 
literature background and our experimental findings, the 
reaction mechanism is proposed and given in Scheme 1. 
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Table 
mL-' 
1 Calibration equations, precision and accuracy at different fixed times for famotidine concentrations in the range of 1 - 8 Hg 
Parameter 
Fixed time methods 
4 min 8 mm 12 min 16 mm 
Calibration equation /I = 0.0124 + 0.0640C -4=0.0166 + 0.06680 A = 0.0044 + 0.0626C A =0.0137 + 0.070IC 
±tS. 0.0146 0.0146 0.0137 0 01972 
±r5b 0.0029 0.0029 0.0027 0 0039 
Molar absorptivity (1 mol-' cm-') 2.176x10" 2.285 X lO' 2.249 X 10^ 2.366 X 10" 
Correlation coefficient 0.9984 0.9986 0.9986 0.9977 
Detection limit (jig mL"') 0.26 0.25 0.25 0.32 
Variance 8.771 X 10-' 8.633 X 10-' 7.657 X 10-' 1.580x 10^ 
%RSD 1.19 1.33 1.20 1.25 
SAE 0.0389 0.0433 0.0393 0.0409 
± tS, = Confidence limit for intercept. ± tSt, = Confidence limit for slope. SAE = Standard analytical error. 
2 
NSOjNH, 
rS-CHjCHj-
HjN 
" " v 
• / • HjN 
< NH2 • 2Mn04"* 20H" 
N^SOjNHa 
\ h 2 
/ 
r S - C H j C H , - C ^ • 2MnO,'-» HjO 
Scheme 1 
Twne (irin) 
Initial-rate method 
The initial rates of the reaction were determined by measuring 
the slopes of the initial tangents to the absorbance time curves 
(Fig. 4). The order with respect to permanganate was estimated 
by studying the reaction at different initial concentrations of 
KMn04 with a fixed famotidine concentration. A plot of the 
initial rate, AAlAt, against the initial absorbance was linear while 
passing through the origin. This indicated that the order of the 
reaction with respect to permanganate at the start was one. The 
order with respcct to famotidine was obtained by plotting the 
log initial rate of the reaction vf. the log molar concentration of 
famotidine, and was found to be unity. 
Under the optimized conditions, the concentration of 
famotidine was determined using an excess of a KMnO* and 
NaOH solution with respect to the initial concentration of 
famotidine. As a consequence, a pseudo zero-order condition 
was obtained with respect to their concentrations. However, the 
initial rate of the reaction would follow a pseudo first-order 
equation. 
Rate = Ml hi - K'C", 
where C is the concentration of famotidine. The above equation 
is transformed into logarithmic equation as 
log(rate) =log AA/&t = log K' + nlog C. 
A regression of the log rate versus log C gave a regression 
equation, 
log(rate) = 3.212 + 1.021 x log C, 
Fig. 4 Absorbance vi. time graph for the reaction between 
famotidine and KMn04, showing the dependence of the reaction on 
famotidine concentration. ( • ) 5.92 x lO"* M; (o) 1.77 x 10"' M and 
( • ) 2.96 X 10-5 M. 
with a correlation coefficient (r) of 0.9971. 
The regression equation also confirmed that the reaction is 
first order with respect to the famotidine concentration. The 
calibration curve was found to be linear over the range 2 - 10 Hg 
mL"'. The confidence limit for the intercept value at the 95% 
confidence level was calculated using the relation a ± tS„^ and 
was found to be 3.212 ± 0.0387, which pointed towards a high 
reproducibility of the method. The detection l imi t ,pe rcen t 
relative standard deviation, standard analytical error and 
variance were found to be 1.68%, 0.0319, and 3.76 x 10^, 
respectively. The small value of the variance confirmed the 
negligible scattering of the calibration data points around the 
line of the regression. 
Fixed-time method 
At a preselected fixed time, the absorbance of a green-colored 
solution containing varying amounts of famotidine was 
measured at 610 nm. Calibration graphs were constructed by 
plotting the absorbance against the initial concentration of 
famotidine at a fixed time of 4, 8, 12 and 16 min. The 
calibration equations, correlation coefficient, detection limit, 
variance and molar absorptivity are given in Table 1. It was 
observed that the most acceptable values of the relative standard 
deviation and the intercept were obtained at a fixed time of 12 
min, and therefore were considered to be the most suitable time 
interval for measurements under this condition. The calibration 
graph was linear over the concentration range of 1 - 8 ng mL"'. 
A strong correlation also existed between the slope and the 
910 ANALYTICAL SCIENCES JUNE 2003, VOL. 19 
Table 4 Detennination of famotidine m commercial tablets by 
the initial rate method and a reference method 
Inlercepi { XI0'^ ) 
Fig 5 Joint confldence region for the slope and intercept of the line 
of regression at 12 mm 
Table 2 Determination of famotidine in pharmaceutical 
preparations by the initial-rate method using the standard 
addition technique 
Formu-
lation* 
Amount 
added/ 
Rg mL-' 
Amount 
taken/ 
Hg mL-' 
Total 
amount 
found/ 
HgmL-' 
Recovery, 
% 
SAE" RSD, 
% 
Topcid 40 2 2 401 100 40 00199 121 
4 2 601 10011 0 0124 050 
3 5 8 01 100 06 0 0579 177 
Famocid 40 2 2 4 01 10018 0 0247 1 51 
4 2 599 99 90 0 0313 I 27 
3 5 7 95 99 47 0 0558 172 
Famotin 40 2 2 3 96 99 20 00230 142 
4 2 5 98 99 82 0 0304 1 24 
3 5 8 02 100 34 0 0443 1 35 
Facid 40 2 2 3 96 99 09 00199 123 
4 2 6 01 100 26 0 0156 0 63 
3 5 7 94 99 36 00544 167 
a Six independent analyses 
b Standard analytical error 
Table 3 Determination of famotidine in pharmaceutical 
preparations by the fixed-time method using the standard 
addition technique 
Formu 
lation' 
Amount 
added/ 
HgmL ' 
Amount 
taken/ 
Hg mL-' 
Total 
amount 
found/ 
JigmL ' 
Recovery, % SAE» RSD, % 
Topcid 40 1 1 1 98 99 38 0 0133 1 64 
2 4 601 100 12 00135 0 55 
3 5 7 96 99 52 0 0195 0 60 
Famocid 40 1 1 1 97 98 85 00112 1 39 
2 4 5 99 99 95 00139 0 56 
3 5 7 97 99 62 00141 0 43 
Famotin 40 1 1 1 96 98 05 00139 1 74 
2 4 601 100 17 0 0192 0 78 
3 5 7 96 99 52 00231 071 
Facid 40 1 1 196 98 45 0 0147 1 82 
2 4 5 99 99 91 0 0152 0 62 
3 5 7 96 99 56 0 0174 0 53 
Formu 
lation 
Proposed method Reference method 
u Recovery,' 
% 
RSD, 
% 
Recovery," 
% 
RSD, 
% 
Topcid 40 100 32 0 96 100 07 0 50 0517 3610 
Famocid 40 99 61 0 73 99 78 0 45 0 485 2 576 
Famotin 40 100 69 1 41 100 03 0 55 1 251 4 335 
Facid 40 99 48 0 78 99 85 0 35 1 064 4 857 
a Average of six independent analyses 
b t-value at 95% confidence level is 1 812 
c F-value at 95% confidence level is 5 05 
Table 5 Determination of famotidine in commercial tablets by 
the fixed-time method and a reference method 
Fonmu 
lation 
Proposed method Reference method 
Recovery," 
% 
RSD, 
% 
Recovery," % RSD, % 
Topcid 40 99 97 102 99 71 071 0 528 2 078 
Famocid 40 10019 1 19 100 00 0 54 0 357 4 724 
Famotin 40 100 08 091 99 42 0 45 1 592 4 184 
Facid 40 10045 0 97 100 14 0 65 1651 2 231 
a Average of six independent analyses 
b t-value at 95% confidence level is 1 812 
c F-value at 95% confidence level is 5 05 
intercept of the caUbraUon line (at a fixed time of 12 nun) This 
was established by drawing a joint confidence region (Fig 5) at 
the 95% confidence level following the method of Mandel and 
Linnig " It IS evident from the figure that the point for which 
the intercept is zero fell well within the ellipse, thus confirming 
no significant difference from zero 
The validity of the proposed methods was tested by adding a 
fixed amount of pure drug to preanalyzed dosage forms The 
results obtained from the investigations are summarized in 
Tables 2 and 3, respectively, which indicated that the common 
additives and excipients did not interfere with the 
determination 
The initial-rate method and fixed-time method were applied to 
the determination of famotidine in commercial dosage forms 
The concentration of the drug was computed from the 
corresponding regression equations The results (Tables 4 and 
5) obtained by the proposed method, were compared 
statistically with that of a reference method,' revealing the fact 
that there is no significant difference in the performance of the 
methods regarding accuracy and precision 
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Abstract 
A simple and fast spectrcphotometnc procedure has been developed for the determination of famotidine The method is based on 
the interaction of nmhydnn with primary amines present in the famotidine This reaction produces a blue coloured product which 
absorbed maximally at 590 nm The effects of vanables such as reagent concentration and reaction time were investigated to 
optimize the procedure Beer's law was obeyed in the concentration range of 5-30 ng m l " ' with molar absorptivity of 6 99 x lO' I 
mol~' c m " ' The results were validated statistically The proposed method has been applied to the determination of famotidine in 
tablets with satisfactory results 
© 2003 Editions scientifiques et medicales Elsevier SAS All rights reserved 
Keywords Famotidine, Nmhydnn, Pharmaceutical formulations, Spectrophotometry 
1. Introduction 
Famotidine (I) is relatively a new histamine H2 
receptor antagonist It is widely used for the treatment 
of duodenal ulcers, benign gastnc ulcer and hyper acid 
secretory conditions such as Zollinger-Ellison syn-
drome [1] Therapeutic trials have shown that famoti-
dine IS twenty times more effective than cimetidme in 
inhibiting gastnc acid secretion m humans [2] The drug 
IS official in European Pharmacopoeia [3] and US [4] 
which described the potentiometric titration and HPLC 
methods for assay of famotidine m pharmaceutical 
formulations Thin layer chromatographic [3,4] and 
high performance thin layer chromatographic methods 
[5] have been reported for purity control of famotidine 
^NSOzNHz 
NH2-' w / 
(I) 
NH2 
A review of literature revealed that several HPLC 
methods have been described for the determination of 
* Corresponding author 
E-mail address chtl7nr_amu@yahoo com (N Rahman) 
famotidine in biological fluids and pharmaceutical 
formulations [6-16] These methods have enough sensi-
tivity to determine lower concentration of the drug and 
hence, it is jusMfied to use them for assay of such a lower 
concentration in biological fluids However, it is always 
required to develop analytical methods using low cost 
techniques UV-Vis spectrophotometry is still consid-
ered a convenient and economical technique for routine 
analysis of the drug in pharmaceutical formulations in 
third world countries 
The famotidine was determined spectrophotometri-
cally [17] based on the reaction of drug with 1,4-
benzoquinone at pH 5 2 Beer's law was obeyed in the 
concentration range of 40-160 Hg m l " ' at 502 nm 
Another spectrophotometric method [18] was described 
which involved the interaction of famotidine with p-
chloranilic acid in acetonitnle and subsequent measure-
ment at 521 nm The first derivative value of interaction 
product with p-chloranilic acid was also measured at 
323 nm Several other spectrophotometric methods [19] 
have also been reported in the literature based on the 
chaige transfer complexation with chloranil, 2,3-di-
chloio 5,6-dicyano l,4-ben2oquinone and dichloioni-
trophenol and absorbance measurements were made at 
458, 460 and 425 nm, respectively Extractive spectro-
photometric methods [20,21] for its determination have 
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been discussed which described extractable l . l ion-pair 
complex between famotidine and each of bromocresol 
green and bromothymol blue. The detection limits were 
found to be 2.0 and 0.7 ng m l " ' for bromocresol green 
and bromothymol blue, respectively. A stability indicat-
ing method was developed based on measuring the peak 
height of the second derivative at 304 nm [22]. The drug 
content in pharmaceuticals was also estimated [23] by 
reaction with sodium nitroprusside in alkaline medium 
resulting in the formation of red coloured complex 
which absorbed maximally at 498 nm. Famotidine was 
determined in tablets by difference spectrophotometric 
and quadratic polynomial coefficient methods [24]. 
A differential pulse voltammetric method [26] was 
suggested based on its electrochemical oxidation at a 
glassy carbon or platinum electrode. It was also 
determined by potentiometric titration [27] with a 
solution of palladium (II) chloride at pH 3.6 using a 
silver electrode. 
ai) 
The present communication describes a spectropho-
tometric method for the determination of famotidine 
based on the reaction of amino group of the drug with 
ninhydrin in A'',iV'-dimethylformamide medium. 
2. Experimental 
2.1. Apparatus 
All spectrophotometric measurements were carried 
out using a spectronic 200"*" spectrophotometer (Milton 
Roy, USA). A water bath shaker (NSW 133, India) was 
used to control the heating temperature. 
2.2. Materials and reagents 
All reagents used were of analytical reagent grade. A 
0.1% famotidine (Wockhardt India Ltd) solution was 
prepared in A'^,A^'-dimethylformamide (DMF) and 
further diluted according to the need with D M F . 
A 0.06 M ninhydrin (E. Merck) solution was also 
prepared in D M F . 
2.3. Procedure for calibration curve 
Aliquots of 0.10-0.60 ml famotidine standard solu-
tion (0.25 mg m l " ' ) were pipetted into a series of boiling 
test tubes. To each test tube 0.7 ml of ninhydrin solution 
was added, mixed well and heated on a water bath at 
100+1 °C for 5 min. After heating the solution, tubes 
were cooled to room temperature. The content of the 
tube was transferred to a 5-ml volumetric flask and 
diluting to volume with D M F . The absorbance was 
measured at 590 nm against reagent blank treated 
similarly. The concentration of famotidine was calcu-
lated either from calibration graph or regression equa-
tion. 
2.4. Procedure for the assay of famotidine in 
pharmaceutical preparations 
Ten tablets were accurately weighed and powdered. A 
portion equivalent to 50 mg famotidine was stirred with 
20 ml D M F and let stand for 10 min. The residue was 
filtered on Whatman No. 42 filter paper and washed 
with D M F . The filtrate and washings were diluted to 
volume in a 50-ml volumetric flask. A suitable volume of 
this solution was further diluted to give a final con-
centration of 0.25 mg m l " A n aliquot of this solution 
was analysed for famotidine following the procedure 
described for the calibration curve. 
3. Results and discussion 
The possible use of ninhydrin for the detection and 
quantitative estimation of amino acids and imino acids 
depends on the formation of Ruhemann purple [28]. It 
was reported that in alkaline medium ninhydrin is 
converted to o-carboxyphenylglyoxal which would re-
duce ninhydrin to 2-hydroxyindan-l,3-dione. The pri-
mary amino group of famotidine reacted with 2-
hydroxyindan-l,3-dione in D M F to form the amino 
compound which condensed with ninhydrin to give 
diketohydrindylidene-diketohydrindamine (II). 
This compound (II) further interacts with amino 
group of the drug resulting in the formation of a blue 
coloured product which absorbed maximally at 590 nm. 
The different experimental parameters influencing the 
intensity of the developed colour were extensively 
investigated to determine the optimal conditions for 
the assay procedure. All conditions studied were opti-
mized in D M F medium. The optimum reaction time was 
determined by heating the reaction mixture on water 
bath at 100 + 1 °C. It is apparent from Fig. 1 that 
complete colour development was attained after 4 min 
of heating and remained constant up to 10 min. There-
fore, the optimum heating time was fixed at 5 min 
throughout the experiment. The effect of ninhydrin 
concentration on the colour development was investi-
gated. For this purpose, different volumes of 0.06 M 
ninhydrin (0.1-1.0 ml) were added to a fixed amount of 
famotidine (25 ng m l " ' ) . The results are presented in 
Fig. 2 which showed that the highest and most stable 
absorbance was obtained with 0.6 ml, beyond which the 
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Table I 
Optical charactenstics and statistical data for the regression equation 
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Fig 1 Effect of heating time on the formation of coloured product 
(drug = 25 ng m l " ' ) 
0.6-
VUuTBcf0 06 Mrinhydrin, ni 
Fig 2 Effect of ninhydnn concentration on the absorbance of the 
coloured product (drug = 25 ng m l " ' ) 
An., (nm) 
Beer's law limit (ng m l " ') 
Molar absorptivity (I mol - ' c m " ' ) 
Sandell's sensitivity (ng m l " ' per 0 001 A) 
Regression equation ' 
Intercept (a) 
Slope (b) 
IS,' 
Correlation coefficient (y) 
Vanance (Sj) 
Lineanty 
Detection limit ( ( n g m l " ' ) 
590 
5 - 3 0 
6 99 X 10' 
4 8 3 x 10"^ 
^ = 0 0 0 6 + 0 0 2 0 5 C 
6 0 0 x 10"^ 
3 11 X 1 0 " ' 
2 0 5 x 10"^ 
1 49 X 1 0 " " 
0 9999 
2 69 X 1 0 " ' 
0 3415 
0 16 
• A =a+bc where c is the concentration in ng m l " ' 
Confidence interval of the intercept at 95% confidence level 
' Confidence interval of the slope at 95% confidence level 
absorbance became constant. A 0.7 ml of the reagent, 
therefore, was used as an optimum value for colour 
development. 
3 1. Analytical data 
In the above established working conditions, the main 
figures of merit of the proposed procedure for determi-
nation of famotidine have been established. The calibra-
tion graph obtained by plotting absorbance at 590 nm 
against famotidine concentration was found to be linear 
over Beer's law range given in the Table 1. The molar 
absorptivity, detection limit [29], variance, slope, inter-
cept, correlation coefficient and linearity obtained by 
least squares treatment of the results are also given m 
Table 1. High value of correlation coefficient confirms 
the excellent linearity of the calibration curve. The value 
of detection limit and variance speak of good sensitivity 
of the proposed method and negligible scatter of the 
Intercept (x 10"^) ^ 
- 4 - 3 - 2 - 1 0 1 2 3 
Slope 
Fig 3 Jomt confidence region for the slope and intercept of line of regression 
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Fig 4 Errors (S'c) m the determination of the concentration of 
famotidine 
calibration data around the line of regression The value 
of intercept is 6 00 x 10"^ and hence it is required to 
judge if the intercept is significantly different from zero 
This has been demonstrated by drawmg a joint con-
fidence region for slope and intercept following the 
method of Mandel and Linnig [30,31] which is an ellipse 
having the point of best fit as its centre It is evident 
from Fig 3 that points for which intercept is zero fell 
well within the ellipse Therefore, it is concluded that the 
intercept is not significantly different from zero and the 
proposed method is free from constant error indepen-
dent of the famotidine concentration 
The absolute error, Sc, in the determination of a given 
concentration of famotidine was calculated by statistical 
analysis of regression equation [30] Fig 4 shows a graph 
of Sc vs concentration of famotidine It is apparent 
from the figure that the error is minimum for a 
concentration of about 17 ng m l " ' of famotidine 
Table 2 
Determination of famotidine in pharmaceutical preparations by standard addition method 
Preparation* Amount taken (ng m l " ' ) Amount added (ng m l " ' ) Total amount found (ng m P ' ) Recovery (%) SAE" RSD(%) 
Topcid 40 10 10 1966 98 33 0 0659 0 82 
10 15 25 08 100 32 0 0319 0 32 
20 10 29 94 99 81 0 0444 0 36 
Famocid 40 10 10 19 68 9S41 0 0393 0 4 9 
10 15 25 008 100 03 0 0498 048 
20 10 29 96 99 89 0 0498 040 
Famotin 40 10 10 19 85 99 26 0 0630 0 77 
10 15 24 98 99 93 0 0526 0 51 
20 10 29 86 99 53 0 0426 034 
Famomte 40 10 10 19 92 99 63 0 0535 0 67 
10 15 24 97 99 90 0 0356 0 34 
20 10 29 91 99 70 0 0609 0 49 
Facid 40 10 10 1991 99 59 0 0709 0 87 
10 15 24 89 99 57 0 0430 0 42 
20 10 29 78 99 29 0 0674 0 55 
* Six independent analyses 
Standard analytical error 
Table 3 
Determination of famotidine in commercial tablets by the proposed and reference method 
Formulation Proposed method Reference method 
Recovery * (%) RSD (%) Recovery " (%) RSD 
Topcid 40 99 70 0 52 99 73 0 30 0 166 2 973 
Famocid 40 100 14 0 65 100 04 0 38 0 430 2 937 
Famotin 40 100 09 0 68 99 86 0 46 0 875 2 193 
Famomte 40 100 14 0 66 100 04 0 38 0411 3 021 
Facid 40 100 00 0 71 99 91 0 49 0 668 2 126 
'' Average of 10 independent analyses 
'' I-Value at 95% confidence level is 1 734 [32) 
' F-vdlue at 95% confidence level is 3 18 (32] 
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Table 4 
Comparison of the proposed method with other existing spectrophotometric methods 
Reagent -Imsx (nm) Beer's law limit (ng ml ') Molar absorptivity (1 mol ' cm ') RSD (%) References 
Sodium nitroprusside 498 5 - 50 5 90 X 10^ 0 15 [23] 
Chloranil 458 50 -500 0 67 X 10' [19] 
;i-Chloranilic acid 521 25 -240 < 2 0 [18] 
1,4-Benzoquinone 502 40 -160 [17] 
D D Q ' 460 40 -450 0 82 X 10' (19] 
D C N P " 425 10 -100 3 70 X 10' [19] 
B C G ' 420 2 - 23 6 5 00 X 10' 1 6 - 3 4 [20] 
BTB" 420 07 - 8 1 1 20 X 10" 1 8 - 3 1 (20] 
Methanol 288 5 - 15 (25] 
Nmhydnn 590 5 - 30 6 9 9 x lO' 0 60-0 94 This work 
" DDQ = 2,3-Dich!oro-5,6-dicyano-l,4-benzoquinone 
^ DCNP = 2,4-Dichloro-6-mtrophenol 
' BCG = Bromocresol green 
BTB = Bromothymol blue 
Reproducibility was measured for a series of ten 
independent determinations at two concentration levels. 
The percent relative standard deviation and standard 
analytical error (SAE) were found to be 0.94%, 0.059 
and 0.60%, 0.057 for the determination of 20 and 30 ng 
m l " ' of famotidine, respectively. 
The validity of the present method was tested by 
standard addition method. For this purpose, solutions 
containing three different concentrations of famotidine 
were prepared by adding a known amount of pure drug 
to the preanalyzed commercial dosage forms and 
determined in six replicates. The results are summarized 
in Table 2 which can be considered to be very 
satisfactory. The common excipients present in tablet 
formulations did not interfere in the determination of 
famotidine. 
The commercial tablets were successfully analyzed for 
famotidine content by the proposed and reference 
methods [23]. The results (Table 3) obtained by both 
the methods were compared statistically. The calculated 
Student's /-and F-values did not exceed the theoretical 
ones at 95% confidence level which confirms the absence 
of any difference between the methods compared. 
The proposed method is favourably compared with 
other existing spectrophotometric methods in terms of 
molar absorptivity and Beer's law limit (Table 4). It is 
evident from Table 4 that present method is more 
sensitive (£ = 6.99 x lO' 1 mol~ ' c m ^ ' ) as compared to 
other reported methods except the method using BTB as 
ion pair formation reagent. However, the Beer's law 
limit of the proposed method is quite reasonable for the 
assay of famotidine in pharmaceutical dosage forms 
with low RSD (0.60-0.94%) in comparison to the 
methods involving extractable ion pair complexes [20]. 
Moreover, the present method is fast and directly 
applicable to the drug sample without prior separation 
or treatment 
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